{"text": "While not significant , there was an increase in the incidence of major bleeding with ELIQUIS compared to aspirin ( 1.41%/year vs. 0.92%/year ) .The incidence of fatal bleeding ( 0.16%/year vs. 0.16%/year ) and intracranial bleeding ( 0.34%/year vs. 0.35%/year ) bleeding were similar in the ELIQUIS and ASA treatment groups .", "label": "", "metadata": {}, "score": "34.53575"}
{"text": "They did , however , identify a reduction in stroke with aspirin for women with diabetes ( RR 0.45 , 95 % CI 0.25 - 0.82 ) ( 17 ) .", "label": "", "metadata": {}, "score": "35.501347"}
{"text": "The overall incidence of adverse reactions related to bleeding with ELIQUIS was 24.3 % in the ELIQUIS vs. warfarin study and was 9.6 % in the ELIQUIS vs. aspirin study .", "label": "", "metadata": {}, "score": "38.721275"}
{"text": "Incidence of major bleeding was 1.4 % per year in the apixaban group whereas 1.2 % in the aspirin group .Acute coronary syndrome .To compare apixaban versus standard antiplatelet therapy in patients with acute coronary syndrome ( ACS ) with at least two risk factors for recurrent ischemia , the Apixaban for Prevention of Acute Ischemic Events 2 ( APPRAISE-2 ) [ 14 ] trial was conducted .", "label": "", "metadata": {}, "score": "39.808132"}
{"text": "Most recently , Steinberg et al .looked into the effect of aspirin therapy with concurrent anticoagulation .They found that major bleeding and bleeding hospitalizations were significantly higher in patients on both oral anticoagulation and aspirin than those patients on oral anticoagulation alone [ 68 ] .", "label": "", "metadata": {}, "score": "42.39364"}
{"text": "These hemorrhagic strokes are incorporated in the estimate of the effect of aspirin on all strokes considered above in question 2 .For extracranial ( mainly gastrointestinal ) bleeding , aspirin use is associated with a 54 % increase in risk based on meta - analysis of the six primary prevention trials ( RR 1.54 , 95 % CI 1.30 - 1.82 ) .", "label": "", "metadata": {}, "score": "44.332916"}
{"text": "Ischaemic stroke events were significantly reduced with dabigatran 150 mg but increased , albeit insignificantly , with dabigatran 110 mg [ 21 ] .Cardiovascular and all - cause mortality were numerically reduced with all three drugs [ 14 , 15 , 21 ] .", "label": "", "metadata": {}, "score": "45.56044"}
{"text": "They also identified potentially important effect modification by sex : aspirin reduced MI for men ( RR 0.57 , 95 % CI 0.34 - 0.94 ) but not for women ( RR 1.08 , 95 % CI 0.71 - 1.65 ) .", "label": "", "metadata": {}, "score": "45.56737"}
{"text": "The proportion of women in the remaining five trials varied from 44 to 56 % .The dose of aspirin varied from 100 mg every other day to 650 mg daily .", "label": "", "metadata": {}, "score": "46.087685"}
{"text": "Aspirin had little effect on CHD death ( RR 0.95 , 95 % CI 0.78 - 1.15 ) or total stroke ( RR 0.95 , 95 % CI 0.85 - 1.06 ) .", "label": "", "metadata": {}, "score": "46.547237"}
{"text": "However , a distinction should be drawn between reversal of coagulation parameters and actual reduction of bleeding [ 41 ] .In another study of mice given supratherapeutic doses of dabigatran , PCC reduced both bleeding time and size of intracerebral haematoma [ 42 ] .", "label": "", "metadata": {}, "score": "47.096497"}
{"text": "Patients were assigned to either aspirin ( 81 - 100 mg daily ) or no aspirin and were followed for an average of 4.4 years .", "label": "", "metadata": {}, "score": "47.271614"}
{"text": "The risk of major bleedings ( table 4 ) was significantly lower with edoxaban 30 mg than any other NOAC , and that of gastrointestinal bleedings was lower with edoxaban 30 mg compared with rivaroxaban and both doses of dabigatran .", "label": "", "metadata": {}, "score": "47.923073"}
{"text": "Other secondary end points did not differ importantly between groups .Overall , mortality occurred in 34 patients in the aspirin group and 38 patients in the nonaspirin group ( HR 0.90 , 95 % CI 0.57 - 1.14 ) .", "label": "", "metadata": {}, "score": "47.945595"}
{"text": "These results were confirmed by Danish registries including more than 130.000 patients with atrial fibrillation : the combination of aspirin and vitamin K antagonists significantly increased the bleeding risk without yielding an additional benefit for stroke reduction compared with vitamin K antagonists only [ 8 ] .", "label": "", "metadata": {}, "score": "48.02133"}
{"text": "Mortality was also reduced , although not reaching statistical significance .Dabigatran applied in a low dose resulted in a significant decrease in major hemorrhage without an increase in ischemic stroke .", "label": "", "metadata": {}, "score": "48.51106"}
{"text": "These trials collectively enrolled over 95,000 participants , including almost 4,000 with diabetes .Overall , the meta - analysis found that aspirin reduced the risk of vascular events by 12 % ( RR 0.88 , 95 % CI 0.82 - 0.94 ) .", "label": "", "metadata": {}, "score": "48.86428"}
{"text": "The Task Force recommended encouraging aspirin use in men age 45 - 79 years and women age 55 - 79 years and not encouraging aspirin use in younger adults .", "label": "", "metadata": {}, "score": "49.188713"}
{"text": "Such analysis , however , did not estimate the benefits of each agent versus imputed placebo and the proportion of the warfarin effect preserved .The present study and that by Skj\u00f8th and coworkers share the conclusion that edoxaban 60 mg is comparable to apixaban , rivaroxaban and the lower dose of dabigatran , but inferior to the higher dose of dabigatran , for prevention of stroke .", "label": "", "metadata": {}, "score": "49.293465"}
{"text": "Aspirin reduced CHD events in men ( RR 0.77 , 95 % CI 0.67 - 0.89 ) but not in women ( RR 0.95 , 95 % CI 0.77 - 1.17 ) .", "label": "", "metadata": {}, "score": "49.480583"}
{"text": "The PPP trial enrolled 1,031 patients with diabetes and found a nonsignificant reduction in the combined MI end point ( fatal plus nonfatal MI ) with 100 mg of aspirin daily compared with placebo ( RR 0.50 , 95 % CI 0.17 - 1.46 ) ( 15 ) .", "label": "", "metadata": {}, "score": "49.563454"}
{"text": "In the ARISTOTLE study , 31 % of the patient received concomitant aspirin medication and a low - percentage ( 1.9 % ) clopidogrel .In the subgroup analysis , there was no significant difference between patients receiving aspirin at randomization and those who did not with regard to stroke and major bleeding ( .", "label": "", "metadata": {}, "score": "49.76552"}
{"text": "Major bleeding events were similar ( 0.6 % rivaroxaban vs. 0.5 % enoxaparin ) .These phase 3 trials showed comparable safety and superior efficacy of rivaroxaban compared with enoxaparin for thromboprophylaxis after hip or knee arthroplasty .", "label": "", "metadata": {}, "score": "50.321335"}
{"text": "There were no significant differences between edoxaban 60 mg and other NOACs for all efficacy outcomes except stroke , which was higher with edoxaban 60 mg than dabigatran 150 mg .", "label": "", "metadata": {}, "score": "50.896652"}
{"text": "Conversely , the lower dose of edoxaban is comparable to the lower dose of dabigatran , but inferior to all other NOACs for prevention of stroke .", "label": "", "metadata": {}, "score": "51.803772"}
{"text": "We also do not have access to sufficient patient - level data in patients with diabetes to consider whether the effect of aspirin on CHD events and stroke differs by sex , the dose of aspirin used , or other clinical factors .", "label": "", "metadata": {}, "score": "52.219612"}
{"text": "This may have been because warfarin is effective in preventing myocardial infarction rather than a hazard of dabigatran [ 39 ] .In contrast , when apixaban was used alone without aspirin , there were numerically fewer myocardial infarctions than warfarin [ 53 ] .", "label": "", "metadata": {}, "score": "52.38327"}
{"text": "Although platelets from patients with diabetes have altered function , it is unclear what , if any , impact that finding has on the required dose of aspirin for cardioprotective outcomes in the diabetic patient ( 29 ) .", "label": "", "metadata": {}, "score": "52.54131"}
{"text": "Gastrointestinal bleeds were increased with dabigatran 150 mg and rivaroxaban , but these did not translate into potentially lethal bleeds for both doses of dabigatran or fatal bleeding with rivaroxaban , the event rates of which were significantly reduced [ 14 , 21 ] .", "label": "", "metadata": {}, "score": "52.864864"}
{"text": "Additionally , a substantial portion of the aspirin - treated population had no clear reason ( such as vascular disease ) to be on the aspirin .", "label": "", "metadata": {}, "score": "52.964012"}
{"text": "The better safety profile in terms of major bleedings compared to all other NOACs , and of gastrointestinal bleedings compared to dabigatran and rivaroxaban , would make the lower dose of edoxaban a reasonable option in patients with high or very high risk of bleeding [ 36 ] .", "label": "", "metadata": {}, "score": "52.9747"}
{"text": "Hence , there is a need for regular monitoring of INR .Aspirin has limited efficacy for stroke prevention in AF .Furthermore the risk of bleeding on aspirin therapy is not inconsiderable [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "53.03186"}
{"text": "OR and 95 % CI are reported in tables 3 ( efficacy outcomes ) and 4 ( safety outcomes ) .The risk of stroke / systemic embolism was significantly higher with edoxaban 30 mg than with dabigatran 150 mg orapixaban .", "label": "", "metadata": {}, "score": "53.037888"}
{"text": "For stroke prevention in AF , dabigatran and apixaban are administered twice daily , and rivaroxaban once daily .Dabigatran is predominantly excreted by the renal route .", "label": "", "metadata": {}, "score": "53.34031"}
{"text": "Major bleeding occurred in a comparable number of patients 30 days post - procedure in the two treatment arms ( 1.57 percent for Eliquis vs. 1.81 percent for warfarin ) .", "label": "", "metadata": {}, "score": "53.355717"}
{"text": "Thus , while the ongoing trials may not provide definitive answers , their combined enrollment of over 15,000 patients will add important new information on the role of aspirin for primary prevention in patients with diabetes .", "label": "", "metadata": {}, "score": "53.49562"}
{"text": "The AVERROES trial showed that apixaban was far more effective ( 46 % relative risk reduction in stroke ) and nearly as safe ( nonsignificant 12 % increase risk of major bleeding and no difference in ICH ) as aspirin [ 34 ] .", "label": "", "metadata": {}, "score": "53.51227"}
{"text": "If these other effective treatments are adopted first , then fewer patients with diabetes will remain at sufficient risk to warrant aspirin use , in light of its potential adverse effects .", "label": "", "metadata": {}, "score": "53.74839"}
{"text": "These recommendations were derived from several older trials that included relatively small numbers of patients with diabetes .Results of two recent randomized controlled trials of aspirin performed specifically in patients with diabetes raised questions about the efficacy of aspirin for primary prevention in diabetes ( 9 , 10 ) .", "label": "", "metadata": {}, "score": "53.824028"}
{"text": "The optimal dosage of aspirin for prevention of cardiovascular events is not clearly established from the outcomes literature .The average daily dose used in the primary prevention trials involving participants with diabetes ranged from 50 to 650 mg daily ( Table 1 ) .", "label": "", "metadata": {}, "score": "53.90005"}
{"text": "Medically ill patients .Orthopedic surgery .Apixaban for the Prevention of Thrombosis - related Events ( ADVANCE ) 1 [ 9 ] assigned 1599patients to receive 2.5 mg twice daily apixaban 12 to 24 hours following knee replacement surgery while 1596 patients received enoxaparin 30 mg subcutaneously twice daily .", "label": "", "metadata": {}, "score": "53.90148"}
{"text": "The most common and most serious adverse reactions reported with ELIQUIS ( apixaban ) were related to bleeding .TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS .", "label": "", "metadata": {}, "score": "54.27018"}
{"text": "The most common and most serious adverse reactions reported with ELIQUIS ( apixaban ) were related to bleeding .TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS .", "label": "", "metadata": {}, "score": "54.27018"}
{"text": "References .Hart RG , Pearce LA , Aguilar MI ( 2007 )Adjusted - dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation .", "label": "", "metadata": {}, "score": "54.336166"}
{"text": "In patients with only one nonmajor risk factor , oral anticoagulation is also the preferred therapy ; alternatively aspirin ( 75 - 325 mg / d ) should be used .", "label": "", "metadata": {}, "score": "54.53807"}
{"text": "The most common and most serious adverse reactions reported with ELIQUIS ( apixaban ) were related to bleeding .DISCONTINUATIONS FOR SURGERY AND OTHER INTERVENTIONS .", "label": "", "metadata": {}, "score": "54.56948"}
{"text": "9 - 19 , 2012 .View at Publisher \u00b7 View at Google Scholar .M. L. Hansen , R. S\u00f8rensen , M. T. Clausen et al . , \" Risk of bleeding with single , dual , or triple therapy with warfarin , aspirin , and clopidogrel in patients with atrial fibrillation , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "54.584316"}
{"text": "A further description of risks and uncertainties can be found in Pfizer 's Annual Report on Form 10-K / A for the fiscal year ended December 31 , 2012 and in its reports on Form 10-Q and Form 8-K. Stroke Prevention in Atrial Fibrillation : Understanding the New Oral Anticoagulants Dabigatran , Rivaroxaban , and Apixaban .", "label": "", "metadata": {}, "score": "54.73278"}
{"text": "Several randomized trials have examined the effect of aspirin for primary prevention of cardiovascular events and have included patients with diabetes ( Table 1 ) .", "label": "", "metadata": {}, "score": "55.24347"}
{"text": "The 110 mg twice - daily dose was found to be noninferior to warfarin for stroke or systemic embolism but had lower rates of major bleeding .", "label": "", "metadata": {}, "score": "55.262268"}
{"text": "Once - a - day dosing differentiates rivaroxaban from dabigatran and apixaban and may enhance patient acceptance and compliance with treatment .Not only are NOACs alternatives to VKAs for stroke prevention in patients with AF , but also they appear to hit the sweet spot of both improved efficacy and safety .", "label": "", "metadata": {}, "score": "55.40112"}
{"text": "Apart from systemic embolism and myocardial infarction , which were higher with edoxaban 30 mg than with rivaroxaban , none of the other outcomes showed statistically significant differences between edoxaban 30 mg and any other NOAC .", "label": "", "metadata": {}, "score": "55.605625"}
{"text": "In addition , apixaban caused less bleeding and resulted in a lower mortality .The ROCKET - AF study included more than 14.000 patients with atrial fibrillation and demonstrated a noninferiority of the factor Xa inhibitor rivaroxaban compared to warfarin for the prevention of stroke or systemic embolism [ 25 ] .", "label": "", "metadata": {}, "score": "55.641487"}
{"text": "In addition , the use of dabigatran as monotherapy might not be a good alternative in these patients .In contrast , fewer patients receiving apixaban had a myocardial infarction than those receiving warfarin in the ARISTOTLE study or aspirin in the AVERROES trial [ 23 , 24 ] .", "label": "", "metadata": {}, "score": "55.654686"}
{"text": "B : Effect of aspirin on risk of stroke in patients with diabetes .For stroke , our random - effects meta - analysis of the nine trials found a reduction in the risk of stroke of 10 % ( RR 0.90 , 95 % CI 0.71 - 1.13 ) that was not statistically significant .", "label": "", "metadata": {}, "score": "55.674965"}
{"text": "160S-198S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Sato , K. Ishikawa , A. Kitabatake et al . , \" Low - dose aspirin for prevention of stroke in low - risk patients with atrial fibrillation : Japan atrial fibrillation stroke trial , \" Stroke , vol .", "label": "", "metadata": {}, "score": "55.77726"}
{"text": "Acknowledgment .This paper was supported by Bayer HealthCare .References .R. G. Hart , L. A. Pearce , and M. I. Aguilar , \" Meta - analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "55.935585"}
{"text": "If ELIQUIS must be discontinued for a reason other than pathological bleeding , consider coverage with another anticoagulant .Bleeding Risk : ELIQUIS increases the risk of bleeding and can cause serious , potentially fatal bleeding .", "label": "", "metadata": {}, "score": "56.048817"}
{"text": "If ELIQUIS must be discontinued for a reason other than pathological bleeding , consider coverage with another anticoagulant .Bleeding Risk : ELIQUIS increases the risk of bleeding and can cause serious , potentially fatal bleeding .", "label": "", "metadata": {}, "score": "56.048817"}
{"text": "If ELIQUIS must be discontinued for a reason other than pathological bleeding , consider coverage with another anticoagulant .Bleeding Risk : ELIQUIS increases the risk of bleeding and can cause serious , potentially fatal bleeding .", "label": "", "metadata": {}, "score": "56.048817"}
{"text": "NOACs are at least equal to VKAs for stroke prevention in AF .Dabigatran 150 mg twice daily and apixaban showed superiority on ITT analyses , the acknowledged gold standard for assessing superiority , while rivaroxaban has superior efficacy based on on - treatment analysis .", "label": "", "metadata": {}, "score": "56.183083"}
{"text": "4 , pp .315 - 322 , 2012 .View at Google Scholar .K. A. Fox , J. P. Piccini , D. Wojdyla , et al . , \" Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non - valvular atrial fibrillation and moderate renal impairment , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "56.20334"}
{"text": "Excluding this trial , the estimate of effect for CHD events was smaller .Meta - analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes .", "label": "", "metadata": {}, "score": "56.342655"}
{"text": "While evidence supports that use of proton - pump inhibitors ( PPIs ) can decrease the risk of recurrent aspirin - related gastrointestinal bleeding ( 25 ) , it is not clear whether routine use of a PPI is cost - effective or should be recommended for primary prevention of gastrointestinal bleeding .", "label": "", "metadata": {}, "score": "56.422768"}
{"text": "In the same population , rising cystatin C levels were independently associated with increased rates of stroke or systemic embolism , mortality , and major bleeding .", "label": "", "metadata": {}, "score": "56.43194"}
{"text": "Vitamin K antagonists ( e.g. , warfarin ) , direct thrombin inhibitors ( dabigatran ) , and factor Xa inhibitors ( rivaroxaban and apixaban ) are all oral anticoagulants that have been FDA approved for the prevention of stroke in atrial fibrillation .", "label": "", "metadata": {}, "score": "56.615894"}
{"text": "Rivaroxaban and dabigatran are also superior to the conventional agents in the management of symptomatic venous thromboembolism .However , compared to enoxaparin , apixaban and rivaroxaban use lead to significantly increased bleeding risk in medically ill patients .", "label": "", "metadata": {}, "score": "56.90345"}
{"text": "What are the needs for future research ?Two ongoing studies will provide additional information on the role of low - dose aspirin for the prevention of cardiovascular events specifically in patients with diabetes .", "label": "", "metadata": {}, "score": "56.99948"}
{"text": "Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P - gp ( e.g. , rifampin , carbamazepine , phenytoin , St. John 's wort ) because such drugs will decrease exposure to apixaban .", "label": "", "metadata": {}, "score": "57.085377"}
{"text": "Anticoagulants and Antiplatelet Agents : Coadministration of antiplatelet agents , fibrinolytics , heparin , aspirin , and chronic NSAID use increases the risk of bleeding .", "label": "", "metadata": {}, "score": "57.179123"}
{"text": "Anticoagulants and Antiplatelet Agents : Coadministration of antiplatelet agents , fibrinolytics , heparin , aspirin , and chronic NSAID use increases the risk of bleeding .", "label": "", "metadata": {}, "score": "57.179123"}
{"text": "A subgroup analysis of ARISTOTLE found that apixaban , compared with warfarin , significantly lowered rates of stroke or systemic embolism across all risk categories for stroke , as well as decreasing major bleeding in all risk categories for bleeding [ 50 ] .", "label": "", "metadata": {}, "score": "57.42514"}
{"text": "B. A. Steinberg , S. Kim , J. P. Piccini , et al . , \" Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation : insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "57.681805"}
{"text": "The higher dose of edoxaban did not differ significantly from any other NOAC in terms of safety outcomes , apart from a lower risk of major bleeding compared to rivaroxaban and higher risk of gastrointestinal bleedings compared to apixaban .", "label": "", "metadata": {}, "score": "57.842014"}
{"text": "Such testing could also allow more precise determination of the dose - response relationship for aspirin in patients both with and without diabetes and better inform the design of large outcomes studies .", "label": "", "metadata": {}, "score": "58.188362"}
{"text": "The bleeding events , including fatal ones , occurred up to several months after initiation of treatment .Some have been linked to use of dabigatran in elderly patients with severe renal impairment , a group that is known to have increased bleeding risk [ 59 ] .", "label": "", "metadata": {}, "score": "58.479248"}
{"text": "Consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis .CONTRAINDICATIONS .Active pathological bleeding .Severe hypersensitivity reaction to ELIQUIS ( apixaban ) ( e.g. , anaphylactic reactions ) .", "label": "", "metadata": {}, "score": "58.56017"}
{"text": "Consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis .CONTRAINDICATIONS .Active pathological bleeding .Severe hypersensitivity reaction to ELIQUIS ( apixaban ) ( e.g. , anaphylactic reactions ) .", "label": "", "metadata": {}, "score": "58.56017"}
{"text": "Given the increase in comorbidities , this population had a higher stroke risk based on CHADS2 and CHA2DS2-VASc scores , as well as increased bleeding risk based on the ATRIA bleeding score .", "label": "", "metadata": {}, "score": "58.6896"}
{"text": "The most common procedures were dental extraction / oral surgery , colonoscopy , upper endoscopy , and ophthalmic surgery .For 4,082 ( 35.8 percent ) procedures , study drug was not stopped .", "label": "", "metadata": {}, "score": "58.712387"}
{"text": "An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation .If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding , coverage with another anticoagulant should be strongly considered .", "label": "", "metadata": {}, "score": "58.731457"}
{"text": "An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation .If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding , coverage with another anticoagulant should be strongly considered .", "label": "", "metadata": {}, "score": "58.731457"}
{"text": "At the point estimate , the lower dose of edoxaban preserved 87 % of the benefit of warfarin on stroke and 133 % of the benefit of warfarin on all - cause mortality .", "label": "", "metadata": {}, "score": "58.746872"}
{"text": "Thus , the use of apixaban or rivaroxaban or a combination of low - dose dabigatran and aspirin might be a good long - term alternative to vitamin K antagonists in patients with atrial fibrillation after stent implantation .", "label": "", "metadata": {}, "score": "58.858627"}
{"text": "One could speculate that this problem might be diminished by the use of new drugs for oral anticoagulation , for instance , dabigatran , rivaroxaban , or apixaban .", "label": "", "metadata": {}, "score": "58.99041"}
{"text": "94 - 102 , 2012 .View at Google Scholar .W. Zhou , S. Schwarting , S. Illanes , et al . , \" Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran , \" Stroke , vol .", "label": "", "metadata": {}, "score": "59.06229"}
{"text": "Further , the effect of Eliquis in reducing the risk of stroke and systemic embolism versus warfarin was also consistent with the results of the ARISTOTLE trial in previously published subanalyses of other comorbidities , including congestive heart failure , advanced age , renal impairment and prior stroke .", "label": "", "metadata": {}, "score": "59.20545"}
{"text": "Further , the effect of Eliquis in reducing the risk of stroke and systemic embolism versus warfarin was also consistent with the results of the ARISTOTLE trial in previously published subanalyses of other comorbidities , including congestive heart failure , advanced age , renal impairment and prior stroke .", "label": "", "metadata": {}, "score": "59.20545"}
{"text": "There are no adequate and well - controlled studies of ELIQUIS in pregnant women .Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery .", "label": "", "metadata": {}, "score": "59.27462"}
{"text": "Recent trials of new oral anticoagulants ( NOACs ) have demonstrated efficacy for stroke prevention in AF and good safety profiles , without detectable hepatotoxicity signals [ 13 - 16 ] .", "label": "", "metadata": {}, "score": "59.4474"}
{"text": "5 , pp .1093 - 1100 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. D. Lopes , S. M. Al - Khatib , L. Wallentin et al . , \" Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "59.563347"}
{"text": "A different , less detailed decision algorithm has been suggested by Paikin et al . in Circulation [ 6 ] .In contrast to the ESC guidelines , oral anticoagulation is temporarily withheld in patients with a high risk of bleeding and a high thromboembolic risk ( Table 5 ) .", "label": "", "metadata": {}, "score": "59.568634"}
{"text": "Fewer than 10 % had had a previous MI or stroke , and 9 % had claudication .Intervention patients experienced a decreased risk of nonfatal or fatal MI ( RR 0.85 , 95 % CI 0.73 - 1.00 ) .", "label": "", "metadata": {}, "score": "59.606"}
{"text": "Commonly available coagulation assays such as PT and aPTT time are not suitable for routine coagulation monitoring of the NOACs , but may provide qualitative information concerning the presence or absence of the drug , especially in the surgical setting .", "label": "", "metadata": {}, "score": "59.611443"}
{"text": "Circulation 116 : 449 - 455 .doi : 10.1161/circulationaha.107.695163 .Lip GY , Edwards SJ ( 2006 )Stroke prevention with aspirin , warfarin and ximelagatran in patients with non - valvular atrial fibrillation : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "59.710293"}
{"text": "LMWH is associated with a reduced rate of adverse effects and have replaced the use of heparin for several indications .Since heparin and LMWH are available only for parenteral use , continuous attempts have been made to develop the oral alternatives of these medications .", "label": "", "metadata": {}, "score": "59.756752"}
{"text": "Similarly , the drug significantly reduced the incidence of VTE in patients of total knee arthroplasty when compared with placebo while the rates of bleeding were similar in both groups [ 34 ] .", "label": "", "metadata": {}, "score": "59.850655"}
{"text": "The ETDRS trial examined the effect of 650 mg of aspirin daily versus placebo among 3,711 patients with type 1 or type 2 diabetes between ages 18 and 70 years who had some degree of retinopathy .", "label": "", "metadata": {}, "score": "59.904716"}
{"text": "9526 , pp .1903 - 1912 , 2006 .View at Publisher \u00b7 View at Google Scholar .M. Man - Son - Hing , G. Nichol , A. Lau , and A. Laupacis , \" Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "59.92756"}
{"text": "Since the primary prevention trials used by the ATT collaboration and by this meta - analysis excluded patients with a history of peptic ulcer disease , the risk calculations for bleeding can not be extended to that population .", "label": "", "metadata": {}, "score": "60.173492"}
{"text": "806 - 817 , 2011 .View at Publisher \u00b7 View at Google Scholar .M. R. Patel , K. W. Mahaffey , J. Garg et al . , \" Rivaroxaban versus warfarin in nonvalvular atrial fibrillation , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "60.26912"}
{"text": "5 , pp .669 - 676 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. A. A. Fox , J. P. Piccini , D. Wojdyla et al . , \" Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non - valvular atrial fibrillation and moderate renal impairment , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "60.515312"}
{"text": "Keywords .Vitamin K antagonists Oral anticoagulants Apixaban Rivaroxaban Dabigatran Orthopedic surgery Knee replacement Hip replacement Acute coronary syndrome Atrial fibrillation Venous thromboembolism Critically ill patients Systematic review .", "label": "", "metadata": {}, "score": "60.62635"}
{"text": "However , a potential benefit of rivaroxaban is the once - daily dose compared to the twice - daily intake of apixaban and dabigatran .In addition , a trend towards a higher risk of myocardial infarctions was seen in patients on dabigatran compared with warfarin , whereas this was not observed for rivaroxaban in the ROCKET - AF trial .", "label": "", "metadata": {}, "score": "60.629364"}
{"text": "The RE - LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for the prevention of stroke ( ischemic and hemorrhagic ) and systemic embolism [ 39 ] .", "label": "", "metadata": {}, "score": "60.635937"}
{"text": "What do we know about the recommended dosage or dosage range ?How can we integrate potential benefits and risks of aspirin to determine which patients with diabetes should receive aspirin for the primary prevention of cardiovascular events ?", "label": "", "metadata": {}, "score": "60.693657"}
{"text": "36 % of the ROCKET - AF study population received concomitant aspirin therapy , up to now a subgroup analysis has not been published [ 25 ] .", "label": "", "metadata": {}, "score": "60.72091"}
{"text": "104 - 123 , 2011 .View at Publisher \u00b7 View at Google Scholar . S. Connolly , J. Pogue , R. Hart , et al . , \" Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events ( ACTIVE W ) : a randomised controlled trial , \" Lancet , vol .", "label": "", "metadata": {}, "score": "60.78495"}
{"text": "What are the potential harms of aspirin , and are these similar or different for people with diabetes compared to those without ?The major adverse effects of aspirin therapy include intracranial bleeding ( hemorrhagic stroke ) and extracranial bleeding , principally gastrointestinal .", "label": "", "metadata": {}, "score": "60.81672"}
{"text": "If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding , coverage with another anticoagulant should be strongly considered .CONTRAINDICATIONS . - Active pathological bleeding .", "label": "", "metadata": {}, "score": "60.8234"}
{"text": "In addition , especially apixaban - possibly in combination with aspirin - might also be a very good alternative to warfarin monotherapy in patients with stable coronary artery disease and atrial fibrillation .", "label": "", "metadata": {}, "score": "60.863586"}
{"text": "There is neither scientific rationale for reversal nor experience with systemic hemostatics ( desmopressin and aprotinin ) in individuals receiving apixaban .Use of procoagulant reversal agents such as prothrombin complex concentrate , activated prothrombin complex concentrate , or recombinant factor VIIa may be considered but has not been evaluated in clinical studies .", "label": "", "metadata": {}, "score": "61.10492"}
{"text": "There is neither scientific rationale for reversal nor experience with systemic hemostatics ( desmopressin and aprotinin ) in individuals receiving apixaban .Use of procoagulant reversal agents such as prothrombin complex concentrate , activated prothrombin complex concentrate , or recombinant factor VIIa may be considered but has not been evaluated in clinical studies .", "label": "", "metadata": {}, "score": "61.10492"}
{"text": "There is neither scientific rationale for reversal nor experience with systemic hemostatics ( desmopressin and aprotinin ) in individuals receiving apixaban .Use of procoagulant reversal agents such as prothrombin complex concentrate , activated prothrombin complex concentrate , or recombinant factor VIIa may be considered but has not been evaluated in clinical studies .", "label": "", "metadata": {}, "score": "61.10492"}
{"text": "The rates of a wide variety of secondary end points and adverse events also did not differ between groups .Outcomes were also similar with or without the antioxidants ; there was no interaction between the two active therapies ( 10 ) .", "label": "", "metadata": {}, "score": "61.171146"}
{"text": "The ESC guidelines on atrial fibrillation recommend a triple therapy consisting of aspirin , clopidogrel , and oral anticoagulation after stent implantation in patients with atrial fibrillation requiring oral anticoagulation .", "label": "", "metadata": {}, "score": "61.178566"}
{"text": "Major bleeding episodes in patients assigned to dabigatran ( 1.6 % ) were also at the same rate ( 1.9 % ) as for patients assigned to warfarin ( hazard ratio with dabigatran , 0.82 ; 95 % CI , 0.45 to 1.48 ) .", "label": "", "metadata": {}, "score": "61.183754"}
{"text": "9745 , pp .975 - 983 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , R. D. Lopes , M. Hanna et al . , \" Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "61.289852"}
{"text": "Trials to date have reached mixed results , but overall suggest that aspirin modestly reduces risk of cardiovascular events .More research is needed to better define the specific effects of aspirin in diabetes , including any sex - specific differences .", "label": "", "metadata": {}, "score": "61.311874"}
{"text": "On the other hand , monotherapy with oral anticoagulation is recommended for patients with stable coronary artery disease and atrial fibrillation ; possibly increasing the risk of cardiac events .", "label": "", "metadata": {}, "score": "61.313507"}
{"text": "In patients without risk factors , the preferred treatment is no antithrombotic therapy rather than aspirin [ 1 ] .However , anticoagulation with vitamin K - antagonists is widely underused in clinical practise , partly due to disadvantages of vitamin - K - antagonists such as cumbersome INR - monitoring or drug interactions [ 5 ] .", "label": "", "metadata": {}, "score": "61.351887"}
{"text": "52 - 61 , 2014 .View at Publisher \u00b7 View at Google Scholar .S. H. Hohnloser , Z. Hijazi , L. Thomas et al . , \" Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "61.413055"}
{"text": "Study medication discontinuation rates were high : 14 % at 1 year and 50 % at 5 years .Overall , 116 of 638 ( 18.2 % ) primary events occurred in patients assigned to aspirin therapy versus 117 of 638 ( 18.3 % ) in those on placebo ( HR 0.98 , 95 % CI 0.76 - 1.26 ) .", "label": "", "metadata": {}, "score": "61.441597"}
{"text": "10.1056/NEJMoa1110899 View Article PubMed .Lassen MR , Raskob GE , Gallus A , Pineo G , Chen D , Portman RJ : Apixaban or enoxaparin for thromboprophylaxis after knee replacement .", "label": "", "metadata": {}, "score": "61.506325"}
{"text": "Thrombosis prevention trial : randomised trial of low - intensity oral anticoagulation with warfarin and low - dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk .", "label": "", "metadata": {}, "score": "61.515614"}
{"text": "In a large Danish registry including more than 40.000 patients with myocardial infarction , yearly bleeding rates in patients receiving triple therapy ( aspirin + clopidogrel + vitamin K antagonist ) or dual therapy consisting of clopidogrel and vitamin K antagonist were 12 % [ 7 ] .", "label": "", "metadata": {}, "score": "61.698578"}
{"text": "However , the combination of oral anticoagulation and antiplatelet therapy increases the bleeding risk .Risk scores such as the CHA 2 DS 2 -Vasc score and the HAS - BLED score help to identify both bleeding and stroke risk in individual patients .", "label": "", "metadata": {}, "score": "61.749054"}
{"text": "AVERROES .As described in the SmPC , the AVERROES ( Apixaban Versus Acetylsalicylic Acid to Prevent Strokes ) trial was designed to demonstrate the efficacy and safety of ELIQUIS versus aspirin for the prevention of stroke or systemic embolism in patients who were unsuitable for VKA therapy .", "label": "", "metadata": {}, "score": "61.77965"}
{"text": "12 , pp .1139 - 1151 , 2009 .View at Google Scholar .M. R. Patel , K. W. Mahaffey , J. Garg , et al . , \" Rivaroxaban versus warfarin in nonvalvular atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "61.803513"}
{"text": "Edoxaban 30 mg and 60 mg preserved 87 % and 112 % , respectively , of the protective effect of warfarin on stroke , and 133 % and 121 % , respectively , of the protective effect of warfarin on all - cause mortality .", "label": "", "metadata": {}, "score": "61.810555"}
{"text": "Since these treatment tools have been used in the past to help guide decisions regarding anticoagulation using vitamin K antagonists and antiplatelet agents , a subgroup analysis of ARISTOTLE was performed to determine the treatment effects of apixaban according to stroke and bleeding [ 50 ] .", "label": "", "metadata": {}, "score": "61.82561"}
{"text": "The Food and Drug Administration has not approved aspirin for use in primary prevention , and its net benefit among patients with no previous cardiovascular events is more controversial , for both patients with and without a history of diabetes ( 5 ) .", "label": "", "metadata": {}, "score": "61.83003"}
{"text": "The HOT trial examined the effect of 75 mg of aspirin daily versus placebo in 18,000 patients ages 50 - 80 years , of whom 1,501 had diabetes .", "label": "", "metadata": {}, "score": "61.918453"}
{"text": "6 , pp .690 - 698 , 2005 .View at Google Scholar . H. C. Diener , \" Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non - valvular atrial fibrillation : pooled analysis from the SPORTIF III and V studies , \" Cerebrovascular Diseases , vol .", "label": "", "metadata": {}, "score": "62.001595"}
{"text": "The first - line use of ELIQUIS and other new oral anticoagulants ( NOACs ) is recommended in The European Society of Cardiology Guidelines for the management of AF where oral anticoagulation is recommended , recognizing the important benefits that ELIQUIS offers in preventing NVAF - related stroke .", "label": "", "metadata": {}, "score": "62.05553"}
{"text": "Thus , the novel oral anticoagulants appear to be a good choice in patients older than 75 years .Elevated Liver Enzymes .Patients with abnormal liver enzymes at baseline were excluded from the novel oral anticoagulant trials as there was concern given that the first oral direct thrombin inhibitor , ximelagatran , caused liver function abnormalities .", "label": "", "metadata": {}, "score": "62.088196"}
{"text": "19 , pp .2369- 2429 , 2010 .View at Google Scholar .R. G. Hart , O. Benavente , R. McBride , and L. A. Pearce , \" Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta - analysis , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "62.13563"}
{"text": "Lancet 1998 ; 351 : 233 - 241 .: Effects of intensive blood - pressure lowering and low - dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment ( HOT ) randomised trial .", "label": "", "metadata": {}, "score": "62.15138"}
{"text": "However , there were no significant differences in the incidence of major bleeding events ( 0.6 % , 0.6 % , and 1.4 % , respectively ) .", "label": "", "metadata": {}, "score": "62.1652"}
{"text": "10 , pp . 883 - 891 , 2011 .View at Google Scholar .C. B. Granger , J. H. Alexander , J. J. McMurray , et al . , \" Apixaban versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "62.185825"}
{"text": "In this review , we have summarized the evidence from phase 3 clinical trials pertaining to the efficacy of apixaban , rivaroxaban , edoxaban and dabigatran in commonly encountered clinical conditions such as acute coronary syndrome , atrial fibrillation , symptomatic venous thromboembolism and orthopedic surgery .", "label": "", "metadata": {}, "score": "62.2436"}
{"text": "The RECORD 2 [ 20 ] trial compared extended duration rivaroxaban ( 31 - 39 days ) to short - term enoxaparin ( 10 - 14 days ) in 2509 patients undergoing total hip arthroplasty .", "label": "", "metadata": {}, "score": "62.30786"}
{"text": "These recommendations depend on the accurate assessment of cardiovascular risk as part of the decision - making process about aspirin use .All patients with diabetes do not have high cardiovascular risk , despite the assumptions of some previous guidelines ( 35 ) .", "label": "", "metadata": {}, "score": "62.311802"}
{"text": "Several strategies apart from the choice of antiplatelet therapy and oral anticoagulation can reduce the risk of bleeding in patients with atrial fibrillation and coronary stenting .", "label": "", "metadata": {}, "score": "62.342056"}
{"text": "The usefulness of dialysis in the setting of overdose or bleeding has been reported in anecdotal cases but has yet to be systematically and rigorously studied .", "label": "", "metadata": {}, "score": "62.433174"}
{"text": "12 , pp .1157 - 1163 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , S. Yusuf , M. D. Ezekowitz et al . , \" Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE - LY trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "62.435883"}
{"text": "A total of 154 events occurred : 68 ( 5.4 % ) in the aspirin group and 86 ( 6.7 % ) in the nonaspirin group ( HR 0.80 , 95 % CI 0.58 - 1.10 ) .", "label": "", "metadata": {}, "score": "62.49541"}
{"text": ": Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes ( JPAD )Trial Investigators .Low - dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial .", "label": "", "metadata": {}, "score": "62.582985"}
{"text": "The ADVANCE 2 [ 10 ] recruited 3057 knee replacement patients to receive the same apixaban dose or enoxaparin 40 mg daily .The Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism 3 ( ADVANCE-3 ) trial [ 11 ] compared 5407 patients undergoing hip arthroplasty to receive either 2.5 mg twice daily apixaban or 40 mg once daily enoxaparin for 5 weeks post - surgery .", "label": "", "metadata": {}, "score": "62.646877"}
{"text": "Reported subanalyses of ROCKET AF confirm the same for rivaroxaban with regard to INR control [ 14 ] , prior stroke status [ 56 ] , prior MI status [ 57 ] , and renal insufficiency [ 58 ] .", "label": "", "metadata": {}, "score": "62.649063"}
{"text": "12 , pp .1139 - 1151 , 2009 .View at Publisher \u00b7 View at Google Scholar .C. B. Granger , J. H. Alexander , J. J.V. McMurray et al . , \" Apixaban versus warfarin in patients with atrial fibrillation , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "62.670013"}
{"text": "Strong Dual Inhibitors of CYP3A4 and P - gp : Inhibitors of CYP3A4 and P - gp increase exposure to apixaban and increase the risk of bleeding .", "label": "", "metadata": {}, "score": "62.68216"}
{"text": "12 , pp .857 - 867 , 2007 .View at Google Scholar \u00b7 View at Scopus . E. M. Hylek , A. S. Go , Y. Chang et al . , \" Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "62.750004"}
{"text": "These patients were randomly assigned in a 1:1 ratio to receive apixaban 5 mg twice daily or matching placebo .Rivaroxaban .Rivaroxaban is another oral , direct acting , reversible factor Xa inhibitor with a rapid onset of action and dose - proportional pharmacokinetics and pharmacodynamics [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "62.9029"}
{"text": "J Thromb Haemost 2008 , 6(8):1313 - 1318 .View Article PubMed .Lassen MR , Davidson BL , Gallus A , Pineo G , Ansell J , Deitchman D : The efficacy and safety of apixaban , an oral , direct factor Xa inhibitor , as thromboprophylaxis in patients following total knee replacement .", "label": "", "metadata": {}, "score": "62.93466"}
{"text": "In addition , further analyses , including analyses according to type of procedures and timing , are ongoing to better define these relationships .\"The U.S. Prescribing Information for Eliquis states that Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding .", "label": "", "metadata": {}, "score": "63.051796"}
{"text": "Thus , both doses of edoxaban were significantly more effective than imputed placebo in reducing the risk of stroke and preserved a substantial proportion of the benefit of warfarin , in line with the FDA guidance [ 48 ] .", "label": "", "metadata": {}, "score": "63.18025"}
{"text": "10.1056/NEJMoa0810773 View Article PubMed .Lassen MR , Raskob GE , Gallus A , Pineo G , Chen D , Hornick P : Apixaban versus enoxaparin for thromboprophylaxis after knee replacement ( ADVANCE-2 ) : a randomised double - blind trial .", "label": "", "metadata": {}, "score": "63.204334"}
{"text": "As the risk of stroke increases , the rate of anticoagulation use is not different or decreases .This may be due to concerns of providers , regarding the risk of bleeding and the risk - benefit tradeoff of treatment for higher - risk populations .", "label": "", "metadata": {}, "score": "63.23422"}
{"text": "The rates of primary efficacy outcome observed in this trial were consistent with those observed in REVOVATE I [ 45 ] .In the RE - MOBILIZE trial [ 48 ] of 1896 patients undergoing total knee arthroplasty , the North American enoxaparin regimen ( 30 mg BID postoperatively ) was used .", "label": "", "metadata": {}, "score": "63.25303"}
{"text": "Moderate risk of falling in the elderly population should not be an absolute contraindication to anticoagulation [ 27 , 36 ] .Warfarin continues to be underused , particularly in the high - risk populations , despite the evidence that the benefit from reduction of thromboembolic events outweighs bleeding risk .", "label": "", "metadata": {}, "score": "63.350895"}
{"text": "1206 - 1214 , 2013 .View at Google Scholar . A. Avezum , R. D. Lopes , P. J. Schulte et al . , \" Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease : findings from the ARISTOTLE study , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "63.44853"}
{"text": "All subjects had an ankle brachial pressure index less than 0.99 but no symptomatic CVD .They were randomized in a 2\u00d72 factorial design to aspirin 100 mg daily , an antioxidant supplement daily , both , or neither .", "label": "", "metadata": {}, "score": "63.45585"}
{"text": "In patients already taking ELIQUIS at a dose of 2.5 mg twice daily , avoid coadministration with strong dual inhibitors of CYP3A4 and P - gp .", "label": "", "metadata": {}, "score": "63.4847"}
{"text": "In patients already taking ELIQUIS at a dose of 2.5 mg twice daily , avoid coadministration with strong dual inhibitors of CYP3A4 and P - gp .", "label": "", "metadata": {}, "score": "63.4847"}
{"text": "In patients already taking ELIQUIS at a dose of 2.5 mg twice daily , avoid coadministration with strong dual inhibitors of CYP3A4 and P - gp .", "label": "", "metadata": {}, "score": "63.4847"}
{"text": "In ARISTOTLE and AVERROES , 24.4 % ( ELIQUIS vs. warfarin ) and 9.6 % ( ELIQUIS vs. aspirin ) of the patients treated with ELIQUIS ( 5 mg or 2.5 mg ) twice daily experienced adverse reactions .", "label": "", "metadata": {}, "score": "63.531433"}
{"text": "Harenberg J , Marx S , Diener HC , Lip GY , Marder VJ , et al .( 2012 ) Comparison of efficacy and safety of dabigatran , rivaroxaban and apixaban in patients with atrial fibrillation using network meta - analysis .", "label": "", "metadata": {}, "score": "63.58815"}
{"text": "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established .DRUG INTERACTIONS .Strong Dual Inhibitors of CYP3A4 and P - gp : Inhibitors of CYP3A4 and P - gp increase exposure to apixaban and increase the risk of bleeding .", "label": "", "metadata": {}, "score": "63.640495"}
{"text": "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established .DRUG INTERACTIONS .Strong Dual Inhibitors of CYP3A4 and P - gp : Inhibitors of CYP3A4 and P - gp increase exposure to apixaban and increase the risk of bleeding .", "label": "", "metadata": {}, "score": "63.640495"}
{"text": "In the present analysis we focused on edoxaban as the latest entry in the available scenario of NOACs .In the ENGAGE AF - TIMI 48 trial , edoxaban 30 mg was also associated with a 53 % lower risk of major bleeding , and a 33 % lower risk of gastrointestinal bleedings versus warfarin .", "label": "", "metadata": {}, "score": "63.880806"}
{"text": "focused their analysis on oral anticoagulant use with increasing stroke and bleeding risk .They found that oral anticoagulant use increased with higher CHADS2 scores but fell slightly with increasing ATRIA bleeding risk .", "label": "", "metadata": {}, "score": "63.922836"}
{"text": "Both doses of edoxaban were non inferior to warfarin for the prevention of stroke and systemic embolism [ 6 ] .Thus far , edoxaban has not yet gained approval by FDA and other regulatory Agencies .", "label": "", "metadata": {}, "score": "63.98803"}
{"text": "9397 , pp .1691 - 1698 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. W. Albers , H. C. Diener , L. Frison , et al . , \" Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation : a randomized trial , \" JAMA , vol .", "label": "", "metadata": {}, "score": "64.246185"}
{"text": "465 - 468 , 1968 .View at Google Scholar \u00b7 View at Scopus .J. Van Ryn , J. Stangier , S. Haertter et al . , \" Dabigatran etexilate - a novel , reversible , oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "64.375565"}
{"text": "11 , pp .2168 - 2175 , 2011 .View at Google Scholar .B. I. Eriksson , L. C. Borris , O. E. Dahl et al . , \" A once - daily , oral , direct Factor Xa inhibitor , rivaroxaban ( BAY 59 - 7939 ) , for thromboprophylaxis after total hip replacement , \" Circulation , vol .", "label": "", "metadata": {}, "score": "64.41945"}
{"text": "5 , pp .634 - 640 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Bahit , R. D. Lopes , D. M. Wojdyla et al . , \" Apixaban in patients with atrial fibrillation and prior coronary disease : insights from the ARISTOTLE trial , \" International Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "64.455864"}
{"text": "9526 , pp .1903 - 1912 , 2006 .View at Google Scholar .S. J. Connolly , M. D. Ezekowitz , S. Yusuf et al . , \" Dabigatran versus warfarin in patients with atrial fibrillation , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "64.49468"}
{"text": "19 , pp .2387 - 2394 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. N. Hess , S. M. Al - Khatib , C. B. Granger , and R. Lopes , \" A review of apixban for stroke prevention in atrial fibrillation : insights from ARISTOTLE , \" Expert Review of Cardiovascular Therapy , vol .", "label": "", "metadata": {}, "score": "64.5948"}
{"text": "The reports of increased bleeding in the postmarketing surveillance phase should be interpreted in context .While several hundred fatal events have occurred , it is impossible to interpret these data without information concerning the total number of patients treated with dabigatran as well as information concerning the expected event rates if these same patients had been treated with warfarin .", "label": "", "metadata": {}, "score": "64.605385"}
{"text": "Nonspecific pro - coagulants , such as nonactivated and activated prothrombin complex concentrate ( PCC ) and recombinant factor VIIa have been advocated for management of major bleeding or rapid reversal for emergency - invasive procedures [ 39 ] .", "label": "", "metadata": {}, "score": "64.63699"}
{"text": "372 - 380 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. N. Beasley , E. F. Unger , and R. Temple , \" Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "64.6519"}
{"text": "Increased Risk of Stroke with Discontinuation of ELIQUIS in Patients with Nonvalvular Atrial Fibrillation : Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .", "label": "", "metadata": {}, "score": "64.80874"}
{"text": "Increased Risk of Stroke with Discontinuation of ELIQUIS in Patients with Nonvalvular Atrial Fibrillation : Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .", "label": "", "metadata": {}, "score": "64.80874"}
{"text": "239 - 245 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. G. Hart , L. A. Pearce , and M. I. Aguilar , \" Meta - analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "64.83087"}
{"text": "14 , 2011 .View at Google Scholar .G. Lu , F. R. Deguzman , M. J. Karbarz , et al . , \" Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein ( r - Antidote , PRT064445 ) , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "64.84153"}
{"text": "1967 - 1974 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Olesen , G. Y. H. Lip , J. Lindhardsen et al . , \" Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation : a net clinical benefit analysis using a \" real world \" nationwide cohort study , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "64.90802"}
{"text": "Conclusion .Considering their pharmacological properties , their efficacy and bleeding complications , the new oral agents offer a net favourable clinical profile in orthopedic surgery , atrial fibrillation , acute coronary syndrome and increase the risk of bleeding in critically ill patients .", "label": "", "metadata": {}, "score": "64.970085"}
{"text": "View at Google Scholar .L. Linkins , P. T. Choi , and J. D. Douketis , \" Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism : a meta - analysis , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "65.10669"}
{"text": "How can we integrate potential benefits and harms of aspirin to determine which patients with diabetes should or should not receive aspirin for the primary prevention of CV events ?", "label": "", "metadata": {}, "score": "65.12986"}
{"text": "WARNINGS AND PRECAUTIONS .Increased Risk of Stroke with Discontinuation of ELIQUIS : Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .", "label": "", "metadata": {}, "score": "65.14525"}
{"text": "Unlike vitamin K antagonists ( VKAs ) , the new oral anticoagulants ( NOACs)-direct thrombin inhibitor , dabigatran , and direct activated factor X inhibitors , rivaroxaban , and apixaban - do not require routine INR monitoring .", "label": "", "metadata": {}, "score": "65.20102"}
{"text": "The New Oral Anticoagulants .Dabigatran , an oral direct thrombin inhibitor , and rivaroxaban and apixaban , both oral direct activated factor X inhibitors , exhibited favourable pharmacodynamics and predictable pharmacokinetic profiles in early phase trials , making them candidate alternatives to VKAs [ 22 - 25 ] .", "label": "", "metadata": {}, "score": "65.22736"}
{"text": "C. N. Hess , S. Broderick , J. P. Piccini et al . , \" Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "65.25234"}
{"text": "( 1 ) Oral anticoagulation is recommended for the majority of patients with atrial fibrillation , and especially a triple therapy with concomitant antiplatelets dramatically increases the risk of bleeding in individual patients .", "label": "", "metadata": {}, "score": "65.354294"}
{"text": "View at Publisher \u00b7 View at Google Scholar .J. L. Mega , E. Braunwald , S. D. Wiviott et al . , \" Rivaroxaban in patients with a recent acute coronary syndrome , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "65.39259"}
{"text": "A specific antidote for ELIQUIS is not available .Hemodialysis does not appear to have a substantial impact on apixaban exposure .Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban .", "label": "", "metadata": {}, "score": "65.51723"}
{"text": "A specific antidote for ELIQUIS is not available .Hemodialysis does not appear to have a substantial impact on apixaban exposure .Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban .", "label": "", "metadata": {}, "score": "65.51723"}
{"text": "In conclusion , in patients who require dual or triple therapy , low - dose dabigatran or apixaban might be a good alternative to warfarin due to good efficacy and rather low bleeding complications .", "label": "", "metadata": {}, "score": "65.52753"}
{"text": "11 , pp .981 - 992 , 2011 .View at Publisher \u00b7 View at Google Scholar .S. J. Connolly , J. Eikelboom , C. Joyner et al . , \" Apixaban in patients with atrial fibrillation , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "65.55408"}
{"text": "The ACTIVE - A trial ( effect of clopidogrel added to aspirin in patients with atrial fibrillation ) assessed the combined therapy of aspirin and clopidogrel in patients with atrial fibrillation who were considered unsuitable for therapy with vitamin K antagonists [ 19 ] .", "label": "", "metadata": {}, "score": "65.611694"}
{"text": "In JPAD , statin use was 26 % , while in PPP lipid - lowering therapy use was 13 % .Three trials ( BMD , PHS , and ETDRS ) were conducted prior to the availability of statins , and TPT and HOT were conducted well before the widespread use of statins for primary prevention .", "label": "", "metadata": {}, "score": "65.68843"}
{"text": "In contrast , aspirin and P2Y12 receptor antagonists do not interfere with PAR-1-dependent platelet activation , and patients on dual antiplatelet therapy remain at risk of cardiovascular events because of alternative pathways of platelet activation [ 30 ] .", "label": "", "metadata": {}, "score": "65.74796"}
{"text": "163 - 174 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier , K. Rathgen , H. St\u00e4hle , D. Gansser , and W. Roth , \" The pharmacokinetics , pharmacodynamics and tolerability of dabigatran etexilate , a new oral direct thrombin inhibitor , in healthy male subjects , \" British Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "65.79542"}
{"text": "APPRAISE-2 , a placebo - controlled clinical trial of apixaban in high - risk post - acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel , was terminated early due to a higher rate of bleeding with apixaban compared to placebo .", "label": "", "metadata": {}, "score": "65.84596"}
{"text": "INDICATION .ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation .ELIQUIS is indicated for the prophylaxis of deep vein thrombosis ( DVT ) , which may lead to pulmonary embolism ( PE ) , in patients who have undergone hip or knee replacement surgery .", "label": "", "metadata": {}, "score": "65.89712"}
{"text": "INDICATION .ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation .ELIQUIS is indicated for the prophylaxis of deep vein thrombosis ( DVT ) , which may lead to pulmonary embolism ( PE ) , in patients who have undergone hip or knee replacement surgery .", "label": "", "metadata": {}, "score": "65.89712"}
{"text": "The recently published EXCELLENT trial ( Six - Month versus Twelve - Month Dual Antiplatelet Therapy after Implantation of Drug - Eluting Stents ) demonstrated a superiority of 12 months of dual antiplatelet therapy compared with 6 months in a subgroup of diabetic patients [ 17 ] .", "label": "", "metadata": {}, "score": "65.94911"}
{"text": "23 , pp .2909 - 2945 , 2008 .View at Publisher \u00b7 View at Google Scholar . E. L. Eisenstein , K. J. Anstrom , D. F. Kong et al . , \" Clopidogrel use and long - term clinical outcomes after drug - eluting stent implantation , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "66.049164"}
{"text": "Therefore , drugs that inhibit P - glycoprotein , such as quinidine , verapamil and amiodarone , will increase the plasma levels of dabigatran [ 43 ] .", "label": "", "metadata": {}, "score": "66.092865"}
{"text": "As these agents become more commonly used in clinical practice , it is imperative for the physicians to be aware of their pharmacological properties .Also , the future studies should attempt to identify effective reversal agents to be used in case of an adverse effect , such as a major bleed .", "label": "", "metadata": {}, "score": "66.1935"}
{"text": "9745 , pp .975 - 983 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. J. Hankey , M. R. Patel , S. R. Stevens , et al . , \" Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of ROCKET AF , \" The Lancet Neurology , vol .", "label": "", "metadata": {}, "score": "66.24131"}
{"text": "The indirect comparison analysis is used to estimate efficacy or safety differences between treatments in the absence of direct head - to - head comparisons [ 39 ] , [ 40 ] .", "label": "", "metadata": {}, "score": "66.26283"}
{"text": "In this analysis , poorly controlled blood pressure at any time during the trial increased the risk of stroke by approximately 50 percent .The results for apixaban compared to warfarin in reducing the risk of stroke were consistent regardless of blood pressure , \" said study lead author Meena Rao , MD , MPH , Duke Clinical Research Institute at Duke University Medical Center .", "label": "", "metadata": {}, "score": "66.30994"}
{"text": "In this analysis , poorly controlled blood pressure at any time during the trial increased the risk of stroke by approximately 50 percent .The results for apixaban compared to warfarin in reducing the risk of stroke were consistent regardless of blood pressure , \" said study lead author Meena Rao , MD , MPH , Duke Clinical Research Institute at Duke University Medical Center .", "label": "", "metadata": {}, "score": "66.30994"}
{"text": ": Aspirin - resistant thromboxane biosynthesis and the risk of myocardial infarction , stroke , or cardiovascular death in patients at high risk for cardiovascular events .", "label": "", "metadata": {}, "score": "66.367294"}
{"text": "Patients were randomized to treatment with Eliquis 5 mg orally twice daily ( or 2.5 mg twice daily in selected patients , representing 4.7 percent of all patients ) or warfarin ( target INR range 2.0 - 3.0 ) , and followed for a median of 1.8 years .", "label": "", "metadata": {}, "score": "66.38337"}
{"text": "What is the evidence regarding aspirin to prevent initial cardiovascular events in people with diabetes ?How can we reconcile the results of the different primary prevention trials ?", "label": "", "metadata": {}, "score": "66.488144"}
{"text": "Warfarin is far more effective than either aspirin or the combination of aspirin and clopidogrel and has comparable bleeding rates [ 31 - 33 ] .", "label": "", "metadata": {}, "score": "66.52439"}
{"text": "However , fatal bleedings especially in older patients and in patients with an impaired renal function have been reported in patients receiving dabigatran .In the ARISTOTLE study , also more than 18.000 patients with atrial fibrillation and a mean CHADS 2 -score of 2.1 were included [ 23 ] .", "label": "", "metadata": {}, "score": "66.54451"}
{"text": "These oral anticoagulants have been approved by the Federal Drug Administration for stroke prevention in patients with AF .In this review , we will focus on a summary of trial results , drug pharmacokinetics and pharmacodynamics , and considerations in high - risk patient populations ( Tables 1 , 2 , and 3 ) [ 37 ] .", "label": "", "metadata": {}, "score": "66.55194"}
{"text": "Atrial fibrillation - related strokes are more severe than other strokes , with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic .", "label": "", "metadata": {}, "score": "66.58702"}
{"text": "Atrial fibrillation - related strokes are more severe than other strokes , with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic .", "label": "", "metadata": {}, "score": "66.58702"}
{"text": "Atrial fibrillation - related strokes are more severe than other strokes , with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic .", "label": "", "metadata": {}, "score": "66.58702"}
{"text": "The dose of dabigatran 110 mg b.i.d . has not been approved in the Unites States by the Food and Drug Administration ( FDA ) , that approved the 75 mg b.i.d . dose in patients with glomerular filtration rate between 15 and 29 ml / min [ 7 ] .", "label": "", "metadata": {}, "score": "66.60263"}
{"text": "Patients with mechanical bileaflet aortic or mitral valves were studied in an open label randomized , blinded endpoint phase II trial that evaluated the safety of dabigatran compared with warfarin , called RE - ALIGN [ 54 ] .", "label": "", "metadata": {}, "score": "66.66277"}
{"text": "In order to synthesize and reconcile the results of the available trials , we examined existing meta - analyses of aspirin prevention trials ( including those that focused on all patients and those that examined only patients with diabetes ) and performed new meta - analyses with updated data .", "label": "", "metadata": {}, "score": "66.73193"}
{"text": "References .114 , pp . e257-e354 , 2006 .View at Publisher \u00b7 View at Google Scholar .W. M. Feinberg , J. L. Blackshear , A. Laupacis , R. Kronmal , and R. G. Hart , \" Prevalence , age distribution , and gender of patients with atrial fibrillation : analysis and implications , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "66.76926"}
{"text": "The POPADAD trial studied whether aspirin and/or antioxidant therapy was more effective than placebo in reducing the incidence of cardiovascular events in patients with diabetes and asymptomatic peripheral arterial disease .", "label": "", "metadata": {}, "score": "66.79364"}
{"text": "Thrombin clotting time tests calibrated to dabigatran , and factor Xa assays calibrated to rivaroxaban have been developed .However , outside of the specific circumstances alluded to above , the use of these tests for dose adjustment of NOACs remains untested and contentious .", "label": "", "metadata": {}, "score": "66.7966"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , S. Yusuf , M. D. Ezekowitz et al . , \" Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE - LY trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "66.88724"}
{"text": "Concurrent therapies .Whether patients have sufficient CVD risk to warrant aspirin use under these assumptions will also depend on the use of other effective techniques for CVD risk reduction , including statins , blood pressure control , and smoking cessation ( 36 , 37 ) .", "label": "", "metadata": {}, "score": "66.9047"}
{"text": "A specific antidote for ELIQUIS is not available .Because of high plasma protein binding , apixaban is not expected to be dialyzable .Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban .", "label": "", "metadata": {}, "score": "66.91241"}
{"text": "10 , pp .1152 - 1160 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier , K. Rathgen , H. Sthle , and D. Mazur , \" Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate : an open - label , parallel - group , single - centre study , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "67.00337"}
{"text": "We estimated the OR of selected events for each dose of edoxaban versus dabigatran ( each dose ) , rivaroxaban and apixaban .The Bucher method assumes that the differences between a given NOAC and warfarin in terms of efficacy and safety would have been analogous if tested in different trial populations exposed to different NOACs versus warfarin [ 16 ] .", "label": "", "metadata": {}, "score": "67.01611"}
{"text": "143 - 149 , 2012 .View at Google Scholar . E. S. Eerenberg , P. W. Kamphuisen , M. K. Sijpkens , et al . , \" Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate : a randomized , placebo - controlled , crossover study in healthy subjects , \" Circulation , vol .", "label": "", "metadata": {}, "score": "67.12088"}
{"text": "Atrial fibrillation - related strokes are more severe than other strokes , with an associated 30-day mortality of 24 % and a 50 % likelihood of death within one year in patients who are not treated with an antithrombotic .", "label": "", "metadata": {}, "score": "67.1262"}
{"text": "The study included patients with AF , aging greater than 65 years , and angiographically confirmed coronary artery disease between 2000 and 2010 .Analysis of this group of patients showed that the use of warfarin was concordant with patient risk , such that there was increased use with higher stroke risk ( defined by CHADS2 and CHA2DS2-VASc scores ) and decreased use with higher bleeding risk ( using the ATRIA score ) .", "label": "", "metadata": {}, "score": "67.247475"}
{"text": "In the dabigatran 110 mg group , .With rivaroxaban , .Table 4 : Relative risk reductions ( RRRs ) of efficacy outcome event rates versus VKA control groups .", "label": "", "metadata": {}, "score": "67.39075"}
{"text": "Of the three NOACs , apixaban demonstrated reduced bleeding ( major and/or nonmajor clinically relevant bleeds ) compared to a VKA . ROCKET AF studied a significantly higher - risk group of AF patients compared to RE - LY and ARISTOTLE , representing the population most difficult to treat who are at increased risk of both thromboembolic events and bleeds .", "label": "", "metadata": {}, "score": "67.428116"}
{"text": "The CHA 2 DS 2 -Vasc - Score is depicted in Table 1 .Numerous studies have demonstrated the superiority of oral anticoagulation compared to antiplatelet therapy in patients with atrial fibrillation and an increased risk for cerebrovascular events [ 2 ] .", "label": "", "metadata": {}, "score": "67.43837"}
{"text": "Thus , even low doses will achieve a full effect after several days of dosing .Additionally , the effects of aspirin begin in the portal circulation and are thereby presystemic .", "label": "", "metadata": {}, "score": "67.45566"}
{"text": "After decades of research novel agents for oral anticoagulation have finally been introduced into the market .New drugs for oral anticoagulation include the direct thrombin inhibitor dabigatran etexilate as well as the factor Xa inhibitors rivaroxaban , apixaban , and edoxaban .", "label": "", "metadata": {}, "score": "67.50713"}
{"text": "The standard antithrombotic agent for patients with coronary artery disease is aspirin ; usually a dual therapy with addition of clopidogrel or newer agents is required after stent implantation or acute coronary syndrome .", "label": "", "metadata": {}, "score": "67.514694"}
{"text": "However , this combination failed to prevent vascular events compared to standard VKA treatment [ 7 ] .The stroke prevention using oral thrombin inhibitor in atrial fibrillation ( SPORTIF AF ) trials , which compared fixed - dose direct thrombin inhibitor ximelagatran with an optimally dose adjusted VKA , provided the first clinical support for the feasibility of chronic anticoagulation without INR monitoring [ 8 - 10 ] .", "label": "", "metadata": {}, "score": "67.52045"}
{"text": "Lancet 1998 ; 351 : 1755 - 1762 .: PPP Collaborative Group .Primary prevention of cardiovascular events with low - dose aspirin and vitamin E in type 2 diabetic patients : results of the Primary Prevention Project ( PPP ) trial .", "label": "", "metadata": {}, "score": "67.53459"}
{"text": "Release : New Eliquis \u00ae ( apixaban ) Post - Hoc Subanalysis of the Phase III ARISTOTLE Trial Demonstrated That Within 30 Days of a Procedure , Stroke or Systemic Embolism and Major Bleeding Were Uncommon .", "label": "", "metadata": {}, "score": "67.62619"}
{"text": "Choosing the most appropriate antithrombotic regimen in this group is challenging , given the increased risk for bleeding related to both age and concomitant antiplatelet therapy .", "label": "", "metadata": {}, "score": "67.68945"}
{"text": "569 - 574 , 2001 .View at Google Scholar \u00b7 View at Scopus .J. L. Mega , E. Braunwald , S. D. Wiviott , et al . , \" Rivaroxaban in patients with a recent acute coronary syndrome , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "67.7203"}
{"text": ": The prevention of progression of arterial disease and diabetes ( POPADAD ) trial : factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease .", "label": "", "metadata": {}, "score": "67.733345"}
{"text": "Strokes secondary to AF have a worse prognosis than in patients without AF [ 12 , 13 ] .Moreover , AF is an independent risk factor for mortality as seen in the Framingham population with an adjusted odds ratio of 1.5 in men and 1.9 in women [ 14 ] .", "label": "", "metadata": {}, "score": "67.746185"}
{"text": "The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation ( ROCKET AF ) [ 23 , 24 ] was conducted in 14,264 patients of non - valvular atrial fibrillation .", "label": "", "metadata": {}, "score": "67.75801"}
{"text": "4 , pp .815 - 825 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. C. Barrett , Z. Wang , C. Frost , and A. Shenker , \" Clinical laboratory measurement of direct factor Xa inhibitors : anti - Xa assay is preferable to prothrombin time assay , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "67.826866"}
{"text": "Notably , any inference about the efficacy of NOACs from these studies assumes that the benefit of warfarin in preventing stroke and systemic embolism approaches that found in prior trials vs placebo or control , as summarized in the above mentioned meta - analysis [ 1 ] .", "label": "", "metadata": {}, "score": "67.97299"}
{"text": "23 , pp .2859 - 2860 , 2005 .View at Google Scholar \u00b7 View at Scopus .S. J. Connolly , M. D. Ezekowitz , S. Yusuf , et al . , \" Dabigatran versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "68.05401"}
{"text": "The ESC guidelines on myocardial revascularisation from 2010 do not address this topic .The duration of clopidogrel after stent implantation has also been much debated .", "label": "", "metadata": {}, "score": "68.08348"}
{"text": "22 , pp .2246 - 2253 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. C. Diener , S. J. Connolly , M. D. Ezekowitz et al . , \" Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke : a subgroup analysis of the RE - LY trial , \" The Lancet Neurology , vol .", "label": "", "metadata": {}, "score": "68.10329"}
{"text": "10 , supplement 1 , abstract A1.E2 , 2010 .View at Google Scholar .M. D. Ezekowitz , L. Wallentin , S. J. Connolly et al . , \" Dabigatran and warfarin in vitamin K antagonist - naive and -experienced cohorts with atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "68.132675"}
{"text": "10.1056/NEJMoa0800374 View Article PubMed .Lancet 2008 , 372(9632):31 - 39 .10.1016/S0140 - 6736(08)60880 - 6 View Article PubMed .Lassen MR , Ageno W , Borris LC , Lieberman JR , Rosencher N , Bandel TJ , Misselwitz F , Turpie AG : Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty .", "label": "", "metadata": {}, "score": "68.13516"}
{"text": "6 , pp .1263 - 1271 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. H. Liesenfeld , T. Lehr , C. Dansirikul , et al . , \" Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non - valvular atrial fibrillation from the RE - LY trial , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "68.16806"}
{"text": "9 - 19 , 2012 .View at Google Scholar .K. Uchino and A. V. Hernandez , \" Dabigatran association with higher risk of acute coronary events : meta - analysis of noninferiority randomized controlled trials , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "68.204605"}
{"text": "Stangier J , St\u00e4hle H , Rathgen K , Reseski K , K\u00f6rnicke T : Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [ abstract].", "label": "", "metadata": {}, "score": "68.23297"}
{"text": "For this analysis , the higher doses of dabigatran ( 150 mg b.i.d . arm of RE - LY [ 3 ] ) and edoxaban ( 60 mg q.d . arm of ENGAGE AF - TIMI 48 [ 6 ] ) were analyzed with data from ROCKET - AF [ 4 ] and ARISTOTLE [ 5 ] .", "label": "", "metadata": {}, "score": "68.26967"}
{"text": "23 , pp .1665 - 1671 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. D. Pokorney , M. W. Sherwood , and R. C. Becker , \" Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation , \" Journal of Thrombosis and Thrombolysis , vol .", "label": "", "metadata": {}, "score": "68.48174"}
{"text": "In patients taking warfarin , the rates of post - procedure major bleeding and death appeared higher when warfarin was continued compared to when it was interrupted .", "label": "", "metadata": {}, "score": "68.537155"}
{"text": "22 , pp . 2422 - 2434 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Gladstone , E. Bui , J. Fang et al . , \" Potentially preventable strokes in high - risk patients with atrial fibrillation who are not adequately anticoagulated , \" Stroke , vol .", "label": "", "metadata": {}, "score": "68.56471"}
{"text": "Given the need for subcutaneous route of administration , long term use of LMWH poses a problem .The new oral anticoagulants specifically target either thrombin or factor Xa ( Figure 1 ) , whereas warfarin inhibits synthesis of all vitamin K - dependant clotting factors .", "label": "", "metadata": {}, "score": "68.6012"}
{"text": "N Engl J Med 323 : 1505 - 1511 .doi : 10.1056/nejm199011293232201 .Koudstaal PJ ( 1993 ) Secondary prevention in non - rheumatic atrial fibrillation after transient ischaemic attack or minor stroke .", "label": "", "metadata": {}, "score": "68.66395"}
{"text": "It is important to note that the current guidelines on anticoagulation in the setting of stent placement were not available at the time these patients were followed .", "label": "", "metadata": {}, "score": "68.67537"}
{"text": "ELIQUIS is an oral direct Factor Xa inhibitor , part of a novel therapeutic class .This is the first regulatory approval in any market for ELIQUIS for stroke prevention in patients with nonvalvular atrial fibrillation .", "label": "", "metadata": {}, "score": "68.71248"}
{"text": "Introduction .Both patients with coronary artery disease as well as patients with atrial fibrillation frequently require antiplatelet therapy or anticoagulation to reduce the risk of cardiovascular and cerebral events .", "label": "", "metadata": {}, "score": "68.72658"}
{"text": "Results are displayed for Dabigatran 150 mg bid .The oral factor Xa - inhibitor edoxaban is currently being tested in patients with atrial fibrillation in the Engage AF TIMI 48 study ( NCT00781391 ) as well as in a Chinese study ( NCT00806624 ) .", "label": "", "metadata": {}, "score": "68.73927"}
{"text": "4 , pp .412 - 421 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. C. Wong , E. J. Crain , B. Xin et al . , \" Apixaban , an oral , direct and highly selective factor Xa inhibitor : in vitro , antithrombotic and antihemostatic studies , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "68.76929"}
{"text": "Although not statistically significant , there were numerically fewer incidents of MI with the factor Xa inhibitors and more with dabigatran , when compared with the VKA arms .", "label": "", "metadata": {}, "score": "68.80173"}
{"text": "Antithrombotic Trialists ' Collaboration .Collaborative meta - analysis of randomised trials of antiplatelet therapy for prevention of death , myocardial infarction , and stroke in high risk patients .", "label": "", "metadata": {}, "score": "68.85576"}
{"text": "The primary efficacy outcome ( total VTE or death ) occurred in 6 % , 8.6 % and 6.7 % of patients in the dabigatran 220 mg , 150 mg and enoxaparin groups , respectively .", "label": "", "metadata": {}, "score": "68.859085"}
{"text": "Weighted average effect versus warfarin .Imputed placebo analysis and proportion of warfarin effect preserved .The comparison of each NOAC versus an imputed placebo on the risk of stroke is shown in figure 2 .", "label": "", "metadata": {}, "score": "68.8693"}
{"text": "This guarded against drug overexposure in subjects with advanced age and low body weight , as age , body weight , gender , and serum creatinine value were incorporated into the equation [ 45 ] .", "label": "", "metadata": {}, "score": "68.95476"}
{"text": "In accordance with the results of the main study , a post - hoc analysis showed that dabigatran 110 mg bid was noninferior to warfarin with regard to stroke and systemic embolism and superior to warfarin in terms of bleeding independent of a concomitant antiplatelet therapy .", "label": "", "metadata": {}, "score": "68.98374"}
{"text": "This resulted in nearly 120 days ' difference between median durations of study drug exposure and study followup .Consequently , ITT analysis that does not take into consideration protocol compliance may not be ideal for demonstration of noninferiority compared to VKAs .", "label": "", "metadata": {}, "score": "69.07622"}
{"text": "14 , pp . 1573- 1579 , 2011 .View at Google Scholar . A. Godier , A. Miclot , B. Le Bonniec , et al . , \" Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model , \" Anesthesiology , vol .", "label": "", "metadata": {}, "score": "69.09061"}
{"text": "292 - 303 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Weinz , T. Schwarz , D. Kubitza , W. Mueck , and D. Lang , \" Metabolism and excretion of rivaroxaban , an oral , direct factor Xa inhibitor , in rats , dogs , and humans , \" Drug Metabolism and Disposition , vol .", "label": "", "metadata": {}, "score": "69.100845"}
{"text": "677 - 685 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. B. Leon , D. S. Baim , J. J. Popma et al . , \" A clinical trial comparing three antithrombotic - drug regimens after coronary - artery stenting , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "69.13454"}
{"text": "Symptomatic venous thromboembolism .In the RE - COVER 1 trial [ 52 ] , patients with acute venous thromboembolism were randomized double - blind to six months of treatment with either dabigatran 150 mg twice daily or warfarin that was dose - adjusted to achieve an INR of 2.0 to 3.0 after initial treatment with a parenteral anticoagulant .", "label": "", "metadata": {}, "score": "69.168915"}
{"text": "In phase 2 clinical trials , apixaban has been shown to provide effective and predictable anticoagulation over the doses of 5 , 10 or 20 mg / day in the prevention and treatment of venous thromboembolism [ 5 , 6 ] .", "label": "", "metadata": {}, "score": "69.25019"}
{"text": "Recent completed phase III trials comparing NOACs with VKAs for stroke prevention in atrial fibrillation ( AF)-the RE - LY , ROCKET AF , and ARISTOTLE trials - demonstrated at least noninferior efficacy , largely driven by significant reductions in haemorrhagic stroke .", "label": "", "metadata": {}, "score": "69.26796"}
{"text": "6 , pp .1116 - 1127 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. M. Samama , J. L. Martinoli , L. LeFlem et al . , \" Assessment of laboratory assays to measure rivaroxaban - an oral , direct factor Xa inhibitor , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "69.310486"}
{"text": "22 , pp .2821 - 2830 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , J. Oldgren , U. Andersson et al . , \" Cystatin C is prognostic for stroke , death and bleeding during anticoagulation of atrial fibrillation - a RELY substudy , \" Circulation , vol .", "label": "", "metadata": {}, "score": "69.33017"}
{"text": "( 2 ) Lifelong oral anticoagulation without concomitant antiplatelet therapy is recommended one year after stent implantation after acute coronary syndrome .Because of an annual rate of late stent thrombosis of about 0.6 % even with antiplatelet therapy and the limitations of vitamin K antagonists to prevent stent thrombosis , a cautious approach to complete termination of antiplatelet therapy seems warranted [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "69.41557"}
{"text": "Major and nonmajor clinically relevant bleeding rates with NOACs are acceptable compared to VKAs .There were significant reductions in intracranial bleeds observed for all the new drugs , the mechanism of which , including the role of membrane transport molecules such as p - gp at the blood - brain barrier , remains to be fully elucidated .", "label": "", "metadata": {}, "score": "69.44186"}
{"text": "Patients taking medications affecting the CYP3A4 pathway ( ketoconazole , clarithromycin , erythromycin , rifampin , and protease inhibitors ) were excluded from the ROCKET - AF trial due to potential drug - drug interactions [ 37 ] .", "label": "", "metadata": {}, "score": "69.53838"}
{"text": "The oral bioavailability of this drug is approximately 6%-7 % , which is much lower than that of the other three oral anticoagulants [ 1 , 4 ] .", "label": "", "metadata": {}, "score": "69.54126"}
{"text": "This may be especially true for important subgroups such as patients on statins , women , and patients with type 1 diabetes .Although ASCEND is powered for a 20 % RR reduction , an RR reduction of 10 % among patients with an underlying incidence of 10 % in the control group would require over 36,000 participants if 90 % power is desired and 26,000 for 80 % power .", "label": "", "metadata": {}, "score": "69.55133"}
{"text": "129 - 139 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. P. Giugliano , C. T. Cuff , E. Braunwald , et al . , \" Edoxaban versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "69.59894"}
{"text": "WARNINGS : ( A ) DISCONTINUING ELIQUIS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE , ( B ) SPINAL / EPIDURAL HEMATOMA .", "label": "", "metadata": {}, "score": "69.67073"}
{"text": "WARNINGS : ( A ) DISCONTINUING ELIQUIS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE , ( B ) SPINAL / EPIDURAL HEMATOMA .", "label": "", "metadata": {}, "score": "69.67073"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .In A Subanalysis , The Benefits Of Eliquis \u00ae ( apixaban )", "label": "", "metadata": {}, "score": "69.91458"}
{"text": "215 - 220 , 2013 .View at Google Scholar .J. W. Eikelboom , S. J. Connolly , M. Brueckmann et al . , \" Dabigatran versus warfarin in patients with mechanical heart valves , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "69.980606"}
{"text": "235 - 240 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. S. Paikin , D. S. Wright , M. A. Crowther , S. R. Mehta , and J. W. Eikelboom , \" Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents , \" Circulation , vol .", "label": "", "metadata": {}, "score": "69.98973"}
{"text": "Baseline characteristics of the study populations in the trials are summarised in Table 3 .All three trials recruited sizable numbers of female , VKA na\u00efve , elderly , and renal - impaired patients .", "label": "", "metadata": {}, "score": "70.05296"}
{"text": "S. B. Olsson , \" Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non - valvular atrial fibrillation ( SPORTIF III ) : randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "70.1347"}
{"text": "Those adults with diabetes at increased CVD risk include most men over age 50 years and women over age 60 years who have one or more of the following additional major risk factors : smoking , hypertension , dyslipidemia , family history of premature CVD , and albuminuria .", "label": "", "metadata": {}, "score": "70.18535"}
{"text": "5 , pp .469 - 473 , 1995 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. M. Novaro , C. R. Asher , D. L. Bhatt et al . , \" Meta - analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in asians versus whites , \" The American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "70.19414"}
{"text": "The ATT collaborators did not identify other clear sources of heterogeneity of effect , although there was some suggestion that current smokers derived less benefit from aspirin than nonsmokers .", "label": "", "metadata": {}, "score": "70.26952"}
{"text": "Baker WL , Phung OJ ( 2012 ) Systematic review and adjusted indirect comparison meta - analysis of oral anticoagulants in atrial fibrillation .Circ Cardiovasc Qual Outcomes 5 : 711 - 719 .", "label": "", "metadata": {}, "score": "70.42325"}
{"text": "ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled .", "label": "", "metadata": {}, "score": "70.55946"}
{"text": "ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled .", "label": "", "metadata": {}, "score": "70.55946"}
{"text": "ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled .", "label": "", "metadata": {}, "score": "70.55946"}
{"text": "Furthermore , the striking reductions in ICH with these NOACs compared to VKAs make these drugs eminently suitable for use in patients at high risk of ICH , a fact best exemplified by ROCKET AF , which recruited patients at high risk of stroke and bleeding .", "label": "", "metadata": {}, "score": "70.62398"}
{"text": "4 , pp .279 - 293 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Brinker , R. He , M. Desai , K. Gelperin , K. Robie - Suh , and V. Gurewich , \" Safety of ximelagatran , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "70.69899"}
{"text": "The results of the RE - LY study were confirmed in the ARISTOTLE biomarker study , showing improvement in risk stratification for overall stroke , as well as for ischemic and for hemorrhagic subtypes , with the addition of NT - proBNP to clinical risk assessment tools [ 18 ] .", "label": "", "metadata": {}, "score": "71.02711"}
{"text": "The available trials ( except ETDRS ) included mainly or exclusively patients with type 2 diabetes .ETDRS enrolled patients with both type 1 and type 2 diabetes ( 31 % type 1 , 31 % type 2 , and 38 % unclassified ) .", "label": "", "metadata": {}, "score": "71.23151"}
{"text": "Rivaroxaban possesses good bioavailability and requires concomitant strong inhibition of intestinal wall p - gp and liver CYP3A4 by drugs like ketoconazole or ritonavir for a clinically significant increase in blood concentrations [ 19 ] .", "label": "", "metadata": {}, "score": "71.306015"}
{"text": "Atrial fibrillation .Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ( ARISTOTLE ) trial [ 12 ] was a comparison between apixaban ( 5 mg twice daily ) and warfarin ( titrated to an INR of 2.0 to 3.0 ) .", "label": "", "metadata": {}, "score": "71.31384"}
{"text": "In animal models , rivaroxaban and apixaban are found in much lower concentrations in the brain compared to plasma [ 61 - 63 ] .P - gp , and possibly other yet to be identified cotransporters , may play a role in this ( rivaroxaban and apixaban , but not active dabigatran , are p - gp substrates )", "label": "", "metadata": {}, "score": "71.3355"}
{"text": "Pharmacodynamics and Pharmacokinetics .Dabigatran inhibits thrombin directly , and potentially the various downstream actions of thrombin [ 26 ] .The highly selective direct inhibitors of factor Xa , rivaroxaban and apixaban , inhibit factor Xa activation of prothrombin to thrombin with limited effects outside the coagulation cascade [ 27 ] .", "label": "", "metadata": {}, "score": "71.3678"}
{"text": "5 , pp .820 - 829 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Wienen , J. M. Stassen , H. Priepke , U. J. Ries , and N. Hauel , \" In - vitro profile and ex - vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug , dabigatran etexilate , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "71.456726"}
{"text": "11 , pp .1398 - 1407 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Wagner , H. Peters , S. Formella , et al . , \" Effective elimination of dabigatran with haemodialysis : a phase I single centre study in patients with end - stage renal disease , \" Circulation , vol .", "label": "", "metadata": {}, "score": "71.482506"}
{"text": "21 , pp .2689 - 2696 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. D. Fihn , C. M. Callahan , D. C. Martin , M. B. McDonell , J. G. Henikoff , and R. H. White , \" The risk for and severity of bleeding complications in elderly patients treated with warfarin , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "71.502884"}
{"text": "Patients receiving apixaban instead of warfarin had lower rates of intracranial bleeding and decreased mortality .Apixaban has 27 % renal excretion .Similar to ROCKET - AF , patients taking medications affecting the CYP3A4 pathway were excluded from ARISTOTLE for potential drug - drug interactions [ 43 ] .", "label": "", "metadata": {}, "score": "71.54679"}
{"text": "Table 3 : Hazard ratios with 95 % CI for subgroup analyses for novel agents versus warfarin .Trial Summaries and Drug Descriptions .The RE - LY trial was an open label randomized trial , which studied dabigatran , a direct thrombin inhibitor .", "label": "", "metadata": {}, "score": "71.64546"}
{"text": "K. Mischke and N. Marx have received speaker 's honoraria from Boehringer - Ingelheim and Pfizer and N. Marx from Bayer .References . A. J. Camm , P. Kirchhof , G. Y. H. Lip , et al . , \" Guidelines for the management of atrial fibrillation : The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology ( ESC ) , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "71.68167"}
{"text": "Despite their efficacy for preventing stroke in patients with AF , VKAs are grossly underused , especially in the elderly : a population with rapidly increasing AF prevalence [ 70 ] that actually stands to benefit the most from VKA treatment .", "label": "", "metadata": {}, "score": "71.727325"}
{"text": "Patients who are at high risk of stroke are identified using the CHADS2 and CHA2DS2-VASc risk classification tools [ 47 , 48 ] .", "label": "", "metadata": {}, "score": "71.77195"}
{"text": "Further essentials of the new oral anticoagulants include a wide therapeutic window , little interaction with food intake , and other drugs compared to vitamin K antagonists .", "label": "", "metadata": {}, "score": "71.784744"}
{"text": "Basically , a triple therapy consisting of a vitamin - K - antagonist , aspirin , and clopidogrel is recommended for a short period of time and a vitamin - K - antagonist alone as lifelong therapy .", "label": "", "metadata": {}, "score": "71.880844"}
{"text": "The U.S. Prescribing Information for Eliquis also includes a Boxed Warning for patients who discontinue treatment .Patients on Eliquis who discontinue treatment are at an increased risk of thrombotic events .", "label": "", "metadata": {}, "score": "71.889946"}
{"text": "N Engl J Med 2011 , 364(9):806 - 817 .10.1056/NEJMoa1007432 View Article PubMed . : Apixaban with antiplatelet therapy after acute coronary syndrome .", "label": "", "metadata": {}, "score": "71.955154"}
{"text": "A significant association between baseline D - dimer levels and risk of stroke , cardiovascular death , and major bleeding was seen in the RE - LY biomarker study and confirmed in the larger ARISTOTLE data set [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "71.996994"}
{"text": "The ARISTOTLE study was designed to demonstrate the efficacy and safety of Eliquis versus warfarin for the prevention of stroke or systemic embolism .In ARISTOTLE , 18,201 patients were randomized ( 9,120 patients to Eliquis and 9,081 to warfarin ) .", "label": "", "metadata": {}, "score": "72.04515"}
{"text": "View at Google Scholar ELIQUIS \u00ae ( apixaban ) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation .", "label": "", "metadata": {}, "score": "72.08083"}
{"text": "11 , pp .1019 - 1026 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Ansell , J. Hirsh , E. Hylek , A. Jacobson , M. Crowther , and G. Palareti , \" Pharmacology and management of the vitamin K antagonists : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines ( 8th Edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "72.18158"}
{"text": "5 , pp .397 - 402 , 2012 .View at Google Scholar .S. H. Hohnloser , J. Oldgren , S. Yang , et al . , \" Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE - LY trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "72.21996"}
{"text": "An individualized approach taking into account the individual risk of stroke , bleeding , myocardial infarction , and stent type is needed to assess the best treatment option , and hopefully new drugs will help to increase both efficacy and safety of the treatment .", "label": "", "metadata": {}, "score": "72.2406"}
{"text": "10.1177/0091270010370974 View Article PubMed .Raskob G , Cohen AT , Eriksson BI , Puskas D , Shi M , Bocanegra T , Weitz JI : Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement .", "label": "", "metadata": {}, "score": "72.269104"}
{"text": "10.2165/11318170 - 000000000 - 00000 View Article PubMed .Stangier J , Rathgen K , St\u00e4hle H , Reseski K , K\u00f6rnicke T , Roth W : Coadministration of dabigatran etexilate and atorvastatin : assessment of potential impact on pharmacokinetics and pharmacodynamics .", "label": "", "metadata": {}, "score": "72.369"}
{"text": "The ATT collaboration authors found that several risk factors for CVD also increased the risk for extracranial bleeding from aspirin , suggesting that those at higher CVD risk are also at higher risk for aspirin - related adverse effects .", "label": "", "metadata": {}, "score": "72.38965"}
{"text": "The education and system - based intervention will be executed over the course of the project .We will prospectively follow the impact of the intervention on clinical outcomes such as admission for stroke , bleeding , and death .", "label": "", "metadata": {}, "score": "72.40124"}
{"text": "22 , pp .2374 - 2381 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Graff , N. Von Hentig , F. Misselwitz et al . , \" Effects of the oral , direct factor Xa inhibitor rivaroxaban on platelet - induced thrombin generation and prothrombinase activity , \" Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "72.53928"}
{"text": "17 , pp .1854 - 1863 , 2011 .View at Publisher \u00b7 View at Google Scholar .P. G. Steg , K. Huber , F. Andreotti et al . , \" Bleeding in acute coronary syndromes and percutaneous coronary interventions : position paper by the Working Group on Thrombosis of the European Society of Cardiology , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "72.663956"}
{"text": "11 , pp .970 - 979 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. D. White , M. Gruber , J. Feyzi et al . , \" Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control results from SPORTIF III and V , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "72.706085"}
{"text": "10.1056/NEJMoa1111096 View Article PubMed .Eriksson BI , Borris LC , Friedman RJ , Haas S , Huisman MV , Kakkar AK , Bandel TJ , Beckmann H , Muehlhofer E , Misselwitz F , Geerts W : Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty .", "label": "", "metadata": {}, "score": "72.74817"}
{"text": "4 , pp .607 - 615 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. M. Hylek , C. Evans - Molina , C. Shea , L. E. Henault , and S. Regan , \" Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "72.76448"}
{"text": "This trial demonstrated a reduction in vascular events in patients on warfarin without an increase in bleeding complications [ 21 ] .Antiplatelet therapy or anticoagulation is thus often warranted both because of an increased stroke risk as well as an increased risk for cardiac events .", "label": "", "metadata": {}, "score": "72.76552"}
{"text": "Important ongoing research is addressing how to safely and effectively use the new drugs in general practice and how to more effectively implement oral anticoagulation , including with warfarin , to better prevent AF - related stroke in the US and around the world .", "label": "", "metadata": {}, "score": "72.803024"}
{"text": "Implementation Research .Despite the effectiveness of anticoagulation , recent literature reviews and studies have documented that current practice does not follow published guidelines , with undertreatment resulting in substantial occurrence of preventable ischemic stroke [ 62 ] .", "label": "", "metadata": {}, "score": "72.812935"}
{"text": "ARISTOTLE .As described in the SmPC , in the ARISTOTLE Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ) trial , ELIQUIS achieved statistically significant superiority in the primary endpoint of prevention of stroke ( haemorrhagic or ischaemic ) and systemic embolism compared with warfarin .", "label": "", "metadata": {}, "score": "72.82758"}
{"text": "Circ J 2011 , 75(8):1852 - 1859 .10.1253/circj . CJ-10 - 1183 View Article PubMed .Goldhaber SZ , Leizorovicz A , Kakkar AK , Haas SK , Merli G , Knabb RM , Weitz JI : Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients .", "label": "", "metadata": {}, "score": "72.846756"}
{"text": "They found no evidence of publication bias based on funnel plots using Begg and Egger tests .Calvin and colleagues ( 21 ) included seven trials from our meta - analysis of patients with diabetes ( they did not include TPT or BMD ) and for MI found RR 0.86 ( 95 % CI 0.67 - 1.11 ) using the seven trials .", "label": "", "metadata": {}, "score": "72.859375"}
{"text": "The lower dose of rivaroxaban in patients with moderate renal impairment showed noninferiority to warfarin therapy in a subgroup analysis [ 45 ] .A subgroup analysis of ARISTOTLE showed a consistent effect for both efficacy and safety across the spectrum of renal function .", "label": "", "metadata": {}, "score": "73.085335"}
{"text": "5 , pp .669 - 676 , 2012 .View at Google Scholar .J. Oldgren , M. Alings , H. Darius , et al . , \" Dabigatran versus warfarin in atrial fibrillation patients with low , moderate and high CHADS2 score : a RE - LY subgroup analysis , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "73.124466"}
{"text": "View at Google Scholar .M. J. Gnoth , U. Buetehorn , U. Muenster , T. Schwarz , and S. Sandmann , \" In vitro and in vivo P - glycoprotein transport characteristics of rivaroxaban , \" Journal of Pharmacology and Experimental Therapeutics , vol .", "label": "", "metadata": {}, "score": "73.126656"}
{"text": "10.2165/0003088 - 200948010 - 00001 View Article PubMed .Buller H , Deitchman D , Prins M , Segers A : Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis .", "label": "", "metadata": {}, "score": "73.13767"}
{"text": "Both doses of dabigatran were therefore better than warfarin .Acute coronary syndrome .In patients with recent ST - elevation or non ST - elevation MI , dabigatran was given in addition to dual antiplatelet therapy in a double - blind , placebo - controlled , dose - escalation phase 2 ( RE - DEEM ) trial [ 50 ] .", "label": "", "metadata": {}, "score": "73.15372"}
{"text": "2370 - 2375 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. D. Furberg , B. M. Psaty , T. A. Manolio et al . , \" Prevalence of atrial fibrillation in elderly subjects ( the Cardiovascular Health Study ) , \" The American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "73.15723"}
{"text": "In patients taking warfarin , there was at least a twofold higher rate of major bleeding and death during the 30-day period following a procedure when warfarin was continued during the procedure compared to when warfarin was stopped prior to the procedure .", "label": "", "metadata": {}, "score": "73.23471"}
{"text": "In diabetic patients over the age of 65 years , 68 % of deaths are from coronary heart disease ( CHD ) and 16 % are from stroke ( 1 ) .", "label": "", "metadata": {}, "score": "73.30054"}
{"text": "BMJ 338 : b1147 . doi : 10.1136/bmj.b1147 .Harenberg J , Marx S , Wehling M ( 2012 )Head - to - head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation : what 's next ?", "label": "", "metadata": {}, "score": "73.37045"}
{"text": "However , robust evidence is lacking for some of the recommendations , and especially for new oral anticoagulants and new antiplatelets few or no data are available .", "label": "", "metadata": {}, "score": "73.40374"}
{"text": "21 , 2011 .View at Google Scholar .J. van Ryn , T. Litzenburger , A. Waterman , et al . , \" Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "73.42113"}
{"text": "15 , pp .1854 - 1864 , 2011 .View at Publisher \u00b7 View at Google Scholar . S. S. Jolly , S. Yusuf , J. Cairns et al . , \" Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes ( RIVAL ) : a randomised , parallel group , multicentre trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "73.52483"}
{"text": "IMPORTANT SAFETY INFORMATION FOR ELIQUIS .BOXED WARNING : DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE .Discontinuing ELIQUIS places patients at an increased risk of thrombotic events .", "label": "", "metadata": {}, "score": "73.60756"}
{"text": "View at Google Scholar . D. S. G. Conway , P. Buggins , E. Hughes , and G. Y. H. Lip , \" Prognostic significance of raised plasma levels of interleukin-6 and C - reactive protein in atrial fibrillation , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "73.651695"}
{"text": "References .Eikelboom JW , Weitz JI : New anticoagulants .Circulation 2010 , 121(13):1523 - 1532 .10.1161/CIRCULATIONAHA.109.853119 View Article PubMed .Altman R , Vidal HO : Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice ( the real world ) perspective .", "label": "", "metadata": {}, "score": "73.65231"}
{"text": "In addition , along with a rapid onset and offset of action , these agents have low potential for dietary interactions .As a result , the new oral agents are more convenient to administer than warfarin and therefore may limit the long term use of warfarin .", "label": "", "metadata": {}, "score": "73.683846"}
{"text": "10.1016/S0140 - 6736(09)62125 - 5 View Article PubMed .Lassen MR , Gallus A , Raskob GE , Pineo G , Chen D , Ramirez LM : Apixaban versus enoxaparin for thromboprophylaxis after hip replacement .", "label": "", "metadata": {}, "score": "73.6965"}
{"text": "Bucher HC , Guyatt GH , Griffith LE , Walter SD ( 1997 )The results of direct and indirect treatment comparisons in meta - analysis of randomized controlled trials .", "label": "", "metadata": {}, "score": "73.69884"}
{"text": "This increasing burden of atrial fibrillation will lead to a higher incidence of stroke , as patients with atrial fibrillation have a five- to sevenfold greater risk of stroke than the general population .", "label": "", "metadata": {}, "score": "73.82252"}
{"text": "Patients receiving rivaroxaban had a lower risk of hemorrhagic stroke and intracranial bleeding compared with warfarin .At baseline , ROCKET - AF had three times as many patients with CHADS2 scores 3 - 6 as RE - LY and ARISTOTLE , resulting in a higher overall risk for thromboembolic events .", "label": "", "metadata": {}, "score": "73.91028"}
{"text": "Although it is estimated that dabigatran concentration would increase about threefold in patients with moderate renal impairment compared to those with normal kidney function [ 46 ] , dabigatran dose was not stratified by CrCl in RE - LY .", "label": "", "metadata": {}, "score": "73.943375"}
{"text": "Thromb Haemost 2010 , 104(3):642 - 649 .10.1160/TH10 - 02 - 0142 View Article PubMed .Fuji T , Fujita S , Tachibana S , Kawai Y : A dose - ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty .", "label": "", "metadata": {}, "score": "73.97034"}
{"text": "22 , pp .2166 - 2176 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. M. Ogilvie , N. Newton , S. A. Welner , W. Cowell , and G. Y. H. Lip , \" Underuse of oral anticoagulants in atrial fibrillation : a systematic review , \" The American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "73.98678"}
{"text": "Similar findings with cystatin C were identified in the RE - LY biomarker study [ 20 ] .While cystatin C had improved risk stratification for stroke , GFR was a better predictor of bleeding , so both markers have the potential to improve risk prediction in patients with AF .", "label": "", "metadata": {}, "score": "74.16554"}
{"text": "Background .Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease .However , these agents have a slow onset of action which requires bridging therapy with heparin and its analogues , which are available only in parenteral route .", "label": "", "metadata": {}, "score": "74.18824"}
{"text": "Eliquis ( apixaban ) is an oral selective Factor Xa inhibitor .By inhibiting Factor Xa , a key blood clotting protein , Eliquis decreases thrombin generation and blood clot formation .", "label": "", "metadata": {}, "score": "74.58742"}
{"text": "Eliquis ( apixaban ) is an oral selective Factor Xa inhibitor .By inhibiting Factor Xa , a key blood clotting protein , Eliquis decreases thrombin generation and blood clot formation .", "label": "", "metadata": {}, "score": "74.58742"}
{"text": "10.1093/eurheartj / ehr113 View Article PubMed .Uchino K , Hernandez AV : Dabigatran association with higher risk of acute coronary events : metaanalysis of noninferiority randomized controlled trials .", "label": "", "metadata": {}, "score": "74.59747"}
{"text": "The efficacy results for prespecified subgroups , including CHADS2 score , age , body weight , gender , renal function , prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial .", "label": "", "metadata": {}, "score": "74.64203"}
{"text": "Each of the novel agents was found to decrease hemorrhagic stroke in patients with a history of previous stroke or TIA .The novel agents should be considered in patients with previous stroke or TIA .", "label": "", "metadata": {}, "score": "74.649124"}
{"text": "There is an association between lower stroke and lower bleeding risk with better INR control as reported from the Stroke Prevention Using ORal Thrombin Inhibitor in Atrial Fibrillation ( SPORTIF ) III and V studies [ 30 ] .", "label": "", "metadata": {}, "score": "74.68803"}
{"text": "An important set of analyses addresses the question of whether the direct oral anticoagulants perform well against warfarin when there is good INR control .This is relevant since a substantial portion of patients currently on warfarin , particularly in anticoagulation clinics or in countries with systems in place to optimize warfarin use , have a \" time in therapeutic range \" of INR 2 - 3 over 65 to 70 % of the time .", "label": "", "metadata": {}, "score": "74.7062"}
{"text": "The trial is still ongoing for patients with a history of myocardial infarction or peripheral arterial disease .The oral PAR-1-receptor antagonist Atopaxar has a shorter half - life than vorapaxar and has been tested in the phase II Lessons from Antagonizing the Cellular Effects of Thrombin ( LANCELOT)-ACS trial .", "label": "", "metadata": {}, "score": "74.75337"}
{"text": "Lip GY , Larsen TB , Skjoth F , Rasmussen LH ( 2012 ) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation .", "label": "", "metadata": {}, "score": "74.7979"}
{"text": "In patients presenting with both coronary artery disease and atrial fibrillation , the choice of medication is sometimes challenging , especially with respect to a possible increase in bleeding complications in patients treated with a dual or triple therapy .", "label": "", "metadata": {}, "score": "74.81663"}
{"text": "More than half of ROCKET AF subjects had prior stroke , and nearly two - thirds had heart failure at baseline .Withdrawal rates at end of study exceeded 20 % in ROCKET AF , ARISTOTLE and the dabigatran arms of RE - LY [ 13 - 15 ] .", "label": "", "metadata": {}, "score": "74.83679"}
{"text": "10.1124/dmd.107.019083 View Article PubMed .Stangier J , Rathgen K , St\u00e4hle H , Mazur D : Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate .", "label": "", "metadata": {}, "score": "74.90044"}
{"text": "This last assumption , however , is conditioned by the differences in patient characteristics , concomitant medications , intensity of treatment , and other trial design features [ 22 ] , [ 24 ] , [ 26 ] , [ 27 ] .", "label": "", "metadata": {}, "score": "74.94525"}
{"text": "5 , pp .713 - 718 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Y. H. Lip , K. Huber , F. Andreotti et al . , \" Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting : executive summary .", "label": "", "metadata": {}, "score": "74.95515"}
{"text": "Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes ( ACCEPT - D ) : design of a randomized study of the efficacy of low - dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins .", "label": "", "metadata": {}, "score": "74.97349"}
{"text": "Key pharmacokinetic characteristics of dabigatran , rivaroxaban and apixaban are summarised in Table 1 [ 18 - 20 ] .Dabigatran etexilate , a prodrug , is hydrolysed by plasma esterases into its active principle , dabigatran , after intestinal absorption ( Figure 1 ) .", "label": "", "metadata": {}, "score": "75.013855"}
{"text": "Due to these observations , the RE - LY trial design required that 50 % of the patients were VKA - na\u00efve .However , the treatment effect of dabigatran did not differ according to prior VKA use .", "label": "", "metadata": {}, "score": "75.02707"}
{"text": "Orthopedic surgery .On the basis of the results of phase 2 studies demonstrating that dabigatran is effective for the prevention of venous thromboembolism ( VTE ) , phase 3 studies for thromboprophylaxis after hip or knee arthroplasty were conducted .", "label": "", "metadata": {}, "score": "75.06062"}
{"text": "Risk Stratification Using Biomarkers .The CHADS2 and CHA2DS2-VASc scores are the primary tools currently used to calculate risk of stroke in patients with AF for the purpose of deciding who has sufficient risk to warrant oral anticoagulation .", "label": "", "metadata": {}, "score": "75.09355"}
{"text": "PubMed Central View Article PubMed .Raghavan N , Frost CE , Yu Z , He K , Zhang H , Humphreys WG , Pinto D , Chen S , Bonacorsi S , Wong PC , Zhang D : Apixaban metabolism and pharmacokinetics after oral administration to humans .", "label": "", "metadata": {}, "score": "75.10049"}
{"text": "Hence , a coating of dabigatran etexilate is applied onto a tartaric acid core to form tiny pellets contained within gel capsules .The higher rates of dyspepsia observed with dabigatran ( versus warfarin ) may be due to the tartaric acid core in the dabigatran formulation [ 32 ] .", "label": "", "metadata": {}, "score": "75.10715"}
{"text": "With regard to vorapaxar , the excess rate in intracranial bleeding is sobering .No clinical data exist with regard to the combination of PAR-1 with warfarin or new anticoagulant drugs .", "label": "", "metadata": {}, "score": "75.108154"}
{"text": "Guidelines recommend VKAs for higher risk AF patients on the basis of estimated efficacy benefits versus the bleeding risk with treatment [ 71 , 72 ] .", "label": "", "metadata": {}, "score": "75.13892"}
{"text": "Finally , the RE - LY biomarker study showed an independent association between IL-6 and stroke or systemic embolism , while CRP levels were associated with cardiovascular mortality after multivariate adjustments [ 17 ] .", "label": "", "metadata": {}, "score": "75.2368"}
{"text": "9855 , pp .1749 - 1758 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. L. Dans , S. J. Connolly , L. Wallentin et al . , \" Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long - term anticoagulation therapy ( RE - LY ) trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "75.237015"}
{"text": "4 , pp .259 - 268 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. A. Penning - Van Beest , E. Van Meegen , F. R. Rosendaal , and B. H. C. Stricker , \" Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "75.24725"}
{"text": "107 , no .6 , pp .1053 - 1065 , 2012 .View at Publisher \u00b7 View at Google Scholar .P. L. Hess , S. Kim , J. P. Piccini et al . , \" Use of evidence - based cardiac prevention therapy among outpatients with atrial fibrillation , \" The American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "75.25949"}
{"text": "Both arms were terminated early due to excess thromboembolic and excess bleeding events in the dabigatran arm .There have also been case reports of patients with mechanical valves developing thrombus on the valves shortly after being changed from warfarin to dabigatran [ 37 , 55 ] .", "label": "", "metadata": {}, "score": "75.33368"}
{"text": "The absorption of this drug is not affected by food intake and it is eliminated primarily through fecal ( 75 % ) but also through renal ( 25 % ) pathway [ 4 ] .", "label": "", "metadata": {}, "score": "75.38426"}
{"text": "This hypothesis is a plausible mechanism for the association between rising levels of NT - proBNP and increased risk of thromboembolic events and cardiovascular mortality in the RE - LY biomarker study [ 17 ] .", "label": "", "metadata": {}, "score": "75.410614"}
{"text": "[ Epub ahead of print ] .Schulman S , Kearon C , Kakkar AK , Mismetti P , Schellong S , Eriksson H , Baanstra D , Schnee J , Goldhaber SZ : Dabigatran versus warfarin in the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "75.42352"}
{"text": "In conclusion , this algorithm is thus less aggressive in anticoagulation therapy than the ESC suggestion .Table 5 : U. S. Anticoagulation regimen after stent implantation ( adopted from Paikin et al . )", "label": "", "metadata": {}, "score": "75.57886"}
{"text": "11 , pp .981 - 992 , 2011 .View at Google Scholar . D. Kubitza , M. Becka , B. Voith , M. Zuehlsdorf , and G. Wensing , \" Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor , \" Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "75.58037"}
{"text": "Understanding why patients are not being treated is necessary to develop targeted strategies to increase the proportion of patients who are treated worldwide .Few quality improvement interventions have been evaluated to determine impact on patient care and clinical outcomes for patients with AF with the goal of decreasing underuse of anticoagulation to reduce preventable stroke rates .", "label": "", "metadata": {}, "score": "75.609314"}
{"text": "Thromb Haemost 2011 , 105(3):535 - 544 .View Article PubMed .Mendell J , Tachibana M , Shi M , Kunitada S : Effects of food on the pharmacokinetics of edoxaban , an oral direct factor Xa inhibitor , in healthy volunteers .", "label": "", "metadata": {}, "score": "75.645615"}
{"text": "5 , pp .1056 - 1064 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. H. Hohnloser , J. Oldgren , S. Yang et al . , \" Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE - LY ( Randomized evaluation of long - term anticoagulation therapy ) trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "75.71576"}
{"text": "Possible disadvantages of the new substances include the lack of antidotes , difficulties in effect monitoring , and the short half - life that might pose a problem in patients with low compliance .", "label": "", "metadata": {}, "score": "75.76773"}
{"text": "The Phase III Clinical Trials : Trial Design .These three studies constitute the largest prospective VKA - controlled trials of anticoagulation for stroke prevention in patients with AF with median followup of about 2 years each ( Table 2 ) .", "label": "", "metadata": {}, "score": "75.87411"}
{"text": "( 2012 ) Antithrombotic therapy for atrial fibrillation : Antithrombotic Therapy and Prevention of Thrombosis , 9th ed : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines .", "label": "", "metadata": {}, "score": "75.90562"}
{"text": "6 , supplement , pp .776S-814S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Van De Werf , J. Bax , A. Betriu et al . , \" Management of acute myocardial infarction in patients presenting with persistent ST - segment elevation , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "76.05528"}
{"text": "The Randomized Evaluation of Long - term Anticoagulant Therapy ( RE - LY ) trial [ 49 ] enrolled 18,113 patients with atrial fibrillation who were at risk for stroke .", "label": "", "metadata": {}, "score": "76.13065"}
{"text": "Anticoagulation represents the mainstay of therapy for most patients with atrial fibrillation .Patients on oral anticoagulation often require concomitant antiplatelet therapy , mostly because of coronary artery disease .", "label": "", "metadata": {}, "score": "76.137726"}
{"text": "Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 . 1 The results showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism , independent of Eliquis or warfarin treatment .", "label": "", "metadata": {}, "score": "76.202896"}
{"text": "Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 . 1 The results showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism , independent of Eliquis or warfarin treatment .", "label": "", "metadata": {}, "score": "76.202896"}
{"text": "However , a different type of bias is introduced because on - treatment analysis may not preserve the integrity of the randomised comparison .Thus , the validity of the on - treatment analysis shall require that subjects excluded from the analysis in both arms of the trial be , at the minimum , balanced in terms of their withdrawal rates , reasons for withdrawal , and baseline characteristics .", "label": "", "metadata": {}, "score": "76.206406"}
{"text": "Data from prospective trials looking at the benefit and risk of combining oral factor Xa - inhibitors or direct thrombin inhibitors with antiplatelet therapy as a dual or triple therapy are missing .", "label": "", "metadata": {}, "score": "76.23312"}
{"text": "This implies that efflux of rivaroxaban from the brain to the blood may be modulated by p - gp action and inhibition .Postmarketing Surveillance of NOACs .", "label": "", "metadata": {}, "score": "76.26865"}
{"text": "The aim of this article is to systematically review the phase 3 clinical trials of new oral anticoagulants in common medical conditions .Methods .The available evidence from the phase 3 RCTs was summarized on the basis of individual drug and the medical conditions categorized into \" atrial fibrillation \" , \" acute coronary syndrome \" , \" orthopedic surgery \" , \" venous thromboembolism \" and \" medically ill patients \" .", "label": "", "metadata": {}, "score": "76.40941"}
{"text": "C. Weinz , U. Buetehorn , H. Daehler , et al . , \" Pharmacokinetics of BAY 59 - 7939-an oral , direct Factor Xa inhibitor - in rats and dogs , \" Pathophysiology of Haemostasis and Thrombosis , vol .", "label": "", "metadata": {}, "score": "76.47525"}
{"text": "We have summarized the findings of phase 3 trials on the new oral anticoagulants .A brief overview of the pharmacological properties of these agents is also presented .", "label": "", "metadata": {}, "score": "76.47754"}
{"text": "Of note , the NOACs caused significantly less intracranial haemorrhagic events compared to VKAs , the mechanisms of which are not completely clear .With convenient fixed - dose administration , the NOACs facilitate anticoagulant management in AF in the community , which has hitherto been grossly underutilised .", "label": "", "metadata": {}, "score": "76.50151"}
{"text": "1 , no .8532 , pp .526 - 529 , 1987 .View at Google Scholar \u00b7 View at Scopus . Y. Miyasaka , M. E. Barnes , K. R. Bailey et al . , \" Mortality Trends in Patients Diagnosed With First Atrial Fibrillation .", "label": "", "metadata": {}, "score": "76.54622"}
{"text": "ELIQUIS is an oral direct Factor Xa inhibitor , part of a new therapeutic class .By inhibiting Factor Xa , a key blood clotting protein , ELIQUIS prevents thrombin generation and blood clot formation .", "label": "", "metadata": {}, "score": "76.607994"}
{"text": "M. C. Fang , A. S. Go , Y. Chang , L. Borowsky , N. K. Pomernacki , and D. E. Singer , \" Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "76.62854"}
{"text": "A RE - LY subanalysis found myocardial ischaemic events ( composite of MI , unstable angina , cardiac arrest , and cardiac death ) to be numerically , albeit not statistically significantly , lower among subjects randomised to dabigatran compared to the VKA [ 51 ] .", "label": "", "metadata": {}, "score": "76.63701"}
{"text": "10.1056/NEJMoa1006885 View Article PubMed . : Apixaban versus warfarin in patients with atrial fibrillation .N Engl J Med 2011 , 365(11):981 - 992 .", "label": "", "metadata": {}, "score": "76.650955"}
{"text": "Each of the trials excluded potential participants at increased risk of gastrointestinal bleeding based on a history of peptic ulcer disease .Therefore , the findings of this meta - analysis , which are based on these trials , can not be readily extended to patients with a history of gastrointestinal bleeding .", "label": "", "metadata": {}, "score": "76.66612"}
{"text": "16 , pp .1433 - 1441 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. L. Dans , S. Connolly , M. Br\u00fcckmann , et al . , \" Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long - term anticoagulation therapy ( RE - LY ) trial , \" in Proceedings of the ESC Congress , Paris , France , 2011 .", "label": "", "metadata": {}, "score": "76.6951"}
{"text": "Dabigatran has been approved by the FDA for patients with a creatinine clearance of 15 - 30 mL / min , albeit with a lower dose that was not tested in the trials [ 69 ] .", "label": "", "metadata": {}, "score": "76.702995"}
{"text": "J. A. Cairns , S. Connolly , S. McMurtry , M. Stephenson , and M. Talajic , \" Canadian cardiovascular society atrial fibrillation guidelines 2010 : prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter , \" Canadian Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "76.72092"}
{"text": "These recommendations can be used as a \" roadmap \" for the management of patients with atrial fibrillation and coronary stenting especially because they are detailed and pragmatic .", "label": "", "metadata": {}, "score": "76.79224"}
{"text": "ELIQUIS is also being investigated in Phase 3 trials for the acute and extended treatment of VTE .Figures .Abstract .Background .Edoxaban recently proved non - inferior to warfarin for prevention of thromboembolism in patients with non - valvular atrial fibrillation ( AF ) .", "label": "", "metadata": {}, "score": "76.80307"}
{"text": "Prior Warfarin Use .Therapy with vitamin K antagonists ( VKA ) has a higher risk of intracranial hemorrhage in the first three months of treatment [ 57 ] .", "label": "", "metadata": {}, "score": "76.8925"}
{"text": "doi : 10.1160/th12 - 07 - 0463 .Skjoth F , Larsen TB , Rasmussen LH ( 2012 ) Indirect comparison studies - are they useful ?", "label": "", "metadata": {}, "score": "76.9548"}
{"text": "doi : 10.1016/j.jacc.2012.03.019 .Rasmussen LH , Larsen TB , Graungaard T , Skjoth F , Lip GY ( 2012 ) Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation : indirect comparison analysis .", "label": "", "metadata": {}, "score": "77.05458"}
{"text": "Prosthetic Heart Valves : The safety and efficacy of ELIQUIS has not been studied in patients with prosthetic heart valves and is not recommended in these patients .", "label": "", "metadata": {}, "score": "77.080666"}
{"text": "The ENGAGE - AF - TIMI48 is a phase 3 noninferiority design megatrial that is comparing edoxaban ( 30 mg or 60 mg once daily ) or warfarin ( titrated to an INR of 2.0 to 3.0 ) in preventing thromboembolism among 20,500 patients of atrial fibrillation [ 36 ] .", "label": "", "metadata": {}, "score": "77.08157"}
{"text": "Crucial for FDA approval was the demonstration of the high probability that enoxaparin retained at least 80 % of the therapeutic effect of unfractionated heparin [ 23 ] .", "label": "", "metadata": {}, "score": "77.11334"}
{"text": "4 , pp .739 - 749 , 2011 .View at Publisher \u00b7 View at Google Scholar .W. Dewilde and J. T. Berg , \" Design and rationale of the WOEST trial : what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing ( WOEST ) , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "77.124825"}
{"text": "640 - 641 , 2011 .View at Google Scholar .S. Ghanny , T. E. Warkentin , and M. A. Crowther , \" Reversing anticoagulant therapy , \" Current Drug Discovery Technologies , vol .", "label": "", "metadata": {}, "score": "77.23927"}
{"text": "Elderly patients with AF have very high risk of thromboembolic events and , given a consistent relative risk reduction with anticoagulation , are a population that has some of the largest benefits from anticoagulation .", "label": "", "metadata": {}, "score": "77.24685"}
{"text": "After the initial feasibility studies [ 27 , 28 ] the EINSTEIN clinical trials program was initiated to test the efficacy of rivaroxaban as a single agent for the management of symptomatic VTE .", "label": "", "metadata": {}, "score": "77.29438"}
{"text": "The aim of the study is to document and increase the rates of appropriate use of oral anticoagulation and patient adherence to and persistence with the treatment plans .", "label": "", "metadata": {}, "score": "77.29513"}
{"text": "Data synthesis and statistical analysis .For safety , we considered major bleeding , intracranial bleeding , gastrointestinal bleeding , myocardial infarction and all - cause death .", "label": "", "metadata": {}, "score": "77.30907"}
{"text": "Eliquis \u00ae ( apixaban ) is an oral direct Factor Xa inhibitor .By inhibiting Factor Xa , a key blood clotting protein , Eliquis prevents thrombin generation and blood clot formation .", "label": "", "metadata": {}, "score": "77.40709"}
{"text": "The RENOVATE II trial [ 47 ] compared 28 to 35 days of treatment with dabigatran 220 mg once daily with subcutaneous enoxaparin 40 mg once daily for prevention of VTE in 2055 patients undergoing total hip arthroplasty .", "label": "", "metadata": {}, "score": "77.53602"}
{"text": "12 , pp .3594 - 3599 , 2011 .View at Google Scholar .J. Beyer - Westendorf and H. Buller , \" External and internal validity of open label or double - blind trials in oral anticoagulation : better , worse or just different ? \"", "label": "", "metadata": {}, "score": "77.6396"}
{"text": "721 - 728 , 2013 .View at Publisher \u00b7 View at Google Scholar . K. He , J. M. Luettgen , D. Zhang et al . , \" Preclinical pharmacokinetics and pharmacodynamics of apixaban , a potent and selective factor Xa inhibitor , \" European Journal of Drug Metabolism and Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "77.66365"}
{"text": "The choice of access site for coronary interventions also has implications on the bleeding risk : radial access , which can also be performed in acute myocardial infarction , is associated with lower bleeding complications than a femoral access [ 34 ] .", "label": "", "metadata": {}, "score": "77.6784"}
{"text": "NOACs fundamentally alter the above - treatment paradigm .With their efficacy for stroke prevention at least equal to VKAs and convenient fixed - dose administration , acceptability among physicians and patients should increase .", "label": "", "metadata": {}, "score": "77.73079"}
{"text": "1605 - 1616 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , L. Wallentin , A. Siegbahn et al . , \" High sensitivity troponin - T and risk stratification in atrial fibrillation during treatment with apixaban or warfarin , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "77.75579"}
{"text": "The AVERROES trial provided some insight into reasons for patients were deemed to be \" unsuitable for warfarin \" with 42 % unable to maintain therapeutic INR , 43 % unlikely to monitor INR , and 37 % refusing warfarin [ 34 ] .", "label": "", "metadata": {}, "score": "77.84831"}
{"text": "10.1007/BF03256595 View Article PubMed .Stangier J , St\u00e4hle H , Rathgen K , Reseski K , K\u00f6rnicke T : No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [ abstract].", "label": "", "metadata": {}, "score": "78.02761"}
{"text": "49 , no . 9 , pp .986 - 992 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. J. Benjamin , P. A. Wolf , R. B. D'Agostino , H. Silbershatz , W. B. Kannel , and D. Levy , \" Impact of atrial fibrillation on the risk of death : the Framingham heart study , \" Circulation , vol .", "label": "", "metadata": {}, "score": "78.15662"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. A. Wolf , R. D. Abbott , and W. B. Kannel , \" Atrial fibrillation : a major contributor to stroke in the elderly .", "label": "", "metadata": {}, "score": "78.2661"}
{"text": "We used the methodology introduced by Hasselblad and Kong to estimate the effects of NOACs versus imputed placebo [ 24 ] .Such approach assumes that previous trials tested warfarin versus placebo using the same outcome event as in the trials of NOACs versus warfarin , and that the populations exposed to trials of warfarin vs placebo and warfarin versus NOACs are similar [ 24 ] .", "label": "", "metadata": {}, "score": "78.26662"}
{"text": "Prior Stroke or TIA .Patients with previous stroke or TIA are at higher risk of major bleeding and stroke or systemic embolism [ 46 ] .", "label": "", "metadata": {}, "score": "78.347984"}
{"text": "This subanalysis was presented today at the ESC Congress 2013 , organized by the European Society of Cardiology , in Amsterdam , The Netherlands .The results showed that in the 30-day period following a procedure , rates of clinical events ( stroke or systemic embolism , major bleeding , and all - cause death ) were comparable in the Eliquis and warfarin treatment arms .", "label": "", "metadata": {}, "score": "78.37998"}
{"text": "After including incident silent MI events , the significant increase in MI was no longer nominally significant .Importantly , the main finding of the RE - LY trial remained unaltered [ 21 ] .", "label": "", "metadata": {}, "score": "78.58946"}
{"text": "These analyses show that whether or not a patient is or has been on warfarin , one can expect the same advantages of the novel agents versus warfarin .", "label": "", "metadata": {}, "score": "78.61696"}
{"text": "22 , pp .2093 - 2104 , 2013 .View at Google Scholar . A. K. Kakkar , I. Mueller , J. P. Bassand , et al . , \" Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke : perspectives from the International , Observational , Prospective GARFIELD registry , \" PloS ONE , vol . 8 , no .", "label": "", "metadata": {}, "score": "78.65694"}
{"text": "As such , they may not predict similar degrees of ICH risk , which are significantly attenuated with NOACs .While extracranial bleeds are still troubling , they do not appear to increase the rates of fatal or potentially fatal bleeds .", "label": "", "metadata": {}, "score": "78.71268"}
{"text": "doi : 10.1016/j.thromres.2005.08.007 .Kistler JP ( 1990 )The effect of low - dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation .", "label": "", "metadata": {}, "score": "78.74807"}
{"text": "Antithrombotic Therapy after Stent Implantation in Patients with Atrial Fibrillation .A practical approach to the management of patients with atrial fibrillation who need oral anticoagulation after coronary artery stenting is presented in the current ESC guidelines for atrial fibrillation [ 1 ] .", "label": "", "metadata": {}, "score": "78.949554"}
{"text": "Active controlled trials might be uninformative as they can neither demonstrate the effectiveness of a new agent nor provide a valid comparison to control therapy unless assay sensitivity can be assured [ 22 ] , [ 23 ] .", "label": "", "metadata": {}, "score": "78.951904"}
{"text": "31 , no .19 , pp .2369- 2429 , 2010 .View at Publisher \u00b7 View at Google Scholar .R. C. Becker , T. W. Meade , P. B. Berger et al . , \" The primary and secondary prevention of coronary artery disease : American College of Chest Physicians evidence - based clinical practice guidelines ( 8th edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "78.96732"}
{"text": "Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room .Discontinue ELIQUIS in patients with active pathological hemorrhage .", "label": "", "metadata": {}, "score": "78.99974"}
{"text": "Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room .Discontinue ELIQUIS in patients with active pathological hemorrhage .", "label": "", "metadata": {}, "score": "78.99974"}
{"text": "Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room .Discontinue ELIQUIS in patients with active pathological hemorrhage .", "label": "", "metadata": {}, "score": "78.99974"}
{"text": "155 - 162 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. G. G. Turpie , \" Oral , direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases , \" Arteriosclerosis , Thrombosis , and Vascular Biology , vol .", "label": "", "metadata": {}, "score": "79.04104"}
{"text": "Perhaps , in the near future , except for male patients younger than 65 years without any other risk factors ( i.e. , CHA2DS2-VASc score 0 ) , all other patients with AF should be anticoagulated , preferably with a NOAC .", "label": "", "metadata": {}, "score": "79.04512"}
{"text": "10.1111/j.1538 -7836.2007.02764.x View Article PubMed .Ogawa S , Shinohara Y , Kanmuri K : Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non - valvular atrial fibrillation .", "label": "", "metadata": {}, "score": "79.099106"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. D. Wiviott , M. D. Flather , M. L. O'Donoghue et al . , \" Randomized trial of atopaxar in the treatment of patients with coronary artery disease : the lessons from antagonizing the cellular effect of thrombin - coronary artery disease trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "79.24036"}
{"text": "Other trials are testing the new drugs for related conditions , including for heart failure and for embolic stroke of undetermined origin , a subset of cryptogenic stroke [ 61 ] .", "label": "", "metadata": {}, "score": "79.266266"}
{"text": "However , in the RELY trial , a nonsignificant increase in myocardial infarction was observed in patients receiving dabigatran compared to warfarin [ 22 ] .", "label": "", "metadata": {}, "score": "79.27777"}
{"text": "Coagulation times as measured by conventional prothrombin time ( PT ) and activated partial thromboplastin time ( aPTT ) are prolonged by the factor Xa antagonists , and dabigatran , respectively [ 29 - 31 ] .", "label": "", "metadata": {}, "score": "79.280914"}
{"text": "6 , pp .1238 - 1247 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. T. Yin and S. Wessler , \" Investigation of the apparent thrombogenicity of thrombin , \" Thrombosis et Diathesis Haemorrhagica , vol .", "label": "", "metadata": {}, "score": "79.360374"}
{"text": "These potential differences in effect by sex were of borderline statistical significance , were affected strongly by the results of one trial ( WHS ) , and can not be considered definitive .", "label": "", "metadata": {}, "score": "79.39862"}
{"text": "Prosthetic Heart Valves : The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients .", "label": "", "metadata": {}, "score": "79.42412"}
{"text": "Prosthetic Heart Valves : The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients .", "label": "", "metadata": {}, "score": "79.42412"}
{"text": "PREGNANCY CATEGORY B .There are no adequate and well - controlled studies of ELIQUIS in pregnant women .Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery .", "label": "", "metadata": {}, "score": "79.64543"}
{"text": "PREGNANCY CATEGORY B .There are no adequate and well - controlled studies of ELIQUIS in pregnant women .Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery .", "label": "", "metadata": {}, "score": "79.64543"}
{"text": "Patients with Prior Coronary Disease .Patients with prior coronary disease appear to have consistent treatment effects with the new drugs versus warfarin for both efficacy and safety .", "label": "", "metadata": {}, "score": "79.648315"}
{"text": "Conclusion .There has been an enormous amount of data generated and analyses performed , including those in collaboration with our research groups at the Duke Clinical Research Institute , regarding oral anticoagulation for preventing stroke in AF .", "label": "", "metadata": {}, "score": "79.68848"}
{"text": "This study suggests that all NOACs preserve a substantial or even larger proportion of the protective warfarin effect on stroke and all - cause mortality .", "label": "", "metadata": {}, "score": "79.795586"}
{"text": "It may be appropriate to distinguish between dabigatran , which is predominantly renally cleared , and the factor Xa inhibitors which are one - quarter to one - third renally cleared .", "label": "", "metadata": {}, "score": "79.84826"}
{"text": "The low risk of intracranial hemorrhage with novel agents may make these medications attractive options for this population .Patients who were older than 75 years were well represented in the oral anticoagulant trials .", "label": "", "metadata": {}, "score": "79.859604"}
{"text": "Stangier J , Clemens A : Pharmacology , pharmacokinetics , and pharmacodynamics of dabigatran etexilate , an oral direct thrombin inhibitor .Clin Appl Thromb Hemost 2009 , 15(Suppl 1):9S-16S. View Article PubMed .", "label": "", "metadata": {}, "score": "79.94275"}
{"text": "10.1016/j.ahj.2010.06.042 View Article PubMed .Blech S , Ebner T , Ludwig - Schwellinger E , Stangier J , Roth W : The metabolism and disposition of the oral direct thrombin inhibitor , dabigatran , in humans .", "label": "", "metadata": {}, "score": "79.95363"}
{"text": "Our findings confirmed the results of a recent meta - analysis [ 46 ] in showing that NOACs , as a whole , are superior to warfarin in reducing the primary composite outcome of stroke / systemic embolism and the secondary outcomes of death and hemorrhagic stroke .", "label": "", "metadata": {}, "score": "79.95933"}
{"text": "Once absorbed into the intestinal bloodstream , dabigatran etexilate is hydrolysed by plasma esterases to its active principle , dabigatran .The latter is no longer a substrate for p - gp efflux .", "label": "", "metadata": {}, "score": "80.10121"}
{"text": "This is counterbalanced by a lower efficacy in the prevention of thromboembolism , although with a final benefit on all - cause mortality .Citation : Verdecchia P , Angeli F , Lip GYH , Reboldi G ( 2014 ) Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons .", "label": "", "metadata": {}, "score": "80.131996"}
{"text": "Anticoagulation with Warfarin in High - Risk Patients .Patients with AF and acute myocardial infarction ( AMI ) are at high risk of death and major cardiovascular outcomes .", "label": "", "metadata": {}, "score": "80.15199"}
{"text": "A proton pump inhibitor can reduce the risk of gastrointestinal bleeding in selected patients [ 36 ] .Conclusion .An individualized approach is needed for patients with atrial fibrillation and coronary artery disease to find the fine balance between the risk of cerebrovascular events and bleeding complications .", "label": "", "metadata": {}, "score": "80.17558"}
{"text": "The two doses of dabigatran tested were double blinded .While both study designs have advantages and limitations , it is worth noting the impact of trial design on outcomes [ 43 ] .", "label": "", "metadata": {}, "score": "80.22017"}
{"text": "On - treatment analysis avoids biases resulting from differential adherence to study drug in a noninferiority trial .This is especially pertinent where treatment is continuous and demanding , and withdrawal rates expected to be high .", "label": "", "metadata": {}, "score": "80.31178"}
{"text": "doi : 10.1016/s0895 - 4356(97)00049 - 8 .Edwards SJ , Clarke MJ , Wordsworth S , Borrill J ( 2009 ) Indirect comparisons of treatments based on systematic reviews of randomised controlled trials .", "label": "", "metadata": {}, "score": "80.45424"}
{"text": "Primary efficacy analyses were intention - to - treat ( ITT ) in RE - LY and ARISTOTLE , and per protocol on - treatment in ROCKET AF .", "label": "", "metadata": {}, "score": "80.561066"}
{"text": "About ARISTOTLE .The ARISTOTLE study was designed to evaluate the efficacy and safety of Eliquis versus warfarin for the prevention of stroke or systemic embolism .", "label": "", "metadata": {}, "score": "80.83584"}
{"text": "About ARISTOTLE .The ARISTOTLE study was designed to evaluate the efficacy and safety of Eliquis versus warfarin for the prevention of stroke or systemic embolism .", "label": "", "metadata": {}, "score": "80.83584"}
{"text": "Conducting indirect - treatment - comparison and network - meta - analysis studies : report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices : part 2 .", "label": "", "metadata": {}, "score": "80.842735"}
{"text": "Concomitant Antiplatelet Therapy .Antiplatelet therapy was given to about 38 % of the population at baseline in the RE - LY trial and about 31 % of the trial population in the ARISTOTLE trial [ 51 , 52 ] .", "label": "", "metadata": {}, "score": "81.00142"}
{"text": "Dabigatran etexilate is an orally active pro - drug which is rapidly converted to dabigatran by esterase - mediated hydrolysis in the plasma and the liver [ 37 ] .", "label": "", "metadata": {}, "score": "81.05354"}
{"text": "In contrast , we also know that about one - quarter of patients with AF have moderate or severe valve abnormalities other than mechanical prosthetic valves or clinically significant mitral stenosis .", "label": "", "metadata": {}, "score": "81.16437"}
{"text": "There is increasing evidence to support risk stratification with the use of biomarkers for myocardial injury , cardiovascular hemodynamic stress , renal dysfunction , coagulation , and inflammation .", "label": "", "metadata": {}, "score": "81.16612"}
{"text": "One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke , which is five times higher in people with atrial fibrillation than those without atrial fibrillation .", "label": "", "metadata": {}, "score": "81.23229"}
{"text": "One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke , which is five times higher in people with atrial fibrillation than those without atrial fibrillation .", "label": "", "metadata": {}, "score": "81.23229"}
{"text": "One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke , which is five times higher in people with atrial fibrillation than those without atrial fibrillation .", "label": "", "metadata": {}, "score": "81.23229"}
{"text": "10.1056/NEJMoa1105819 View Article PubMed .Kubitza D , Becka M , Roth A , Mueck W : Dose - escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects .", "label": "", "metadata": {}, "score": "81.23537"}
{"text": "Co- administration of dabigatran with atorvastatin ( a substrate for CYP3A4 and P - glycoprotein ) [ 40 ] , digoxin ( a P - glycoprotein substrate ) [ 41 ] or diclofenac ( a CYP2C9 substrate ) [ 42 ] did not result in clinically relevant drug interactions .", "label": "", "metadata": {}, "score": "81.23835"}
{"text": "Enoxaparin prevents death and cardiac ischemic events in unstable angina / non - Q - wave myocardial infarction .Results of the thrombolysis in myocardial infarction ( TIMI )", "label": "", "metadata": {}, "score": "81.24533"}
{"text": "Dabigatran is predominately ( 80 % ) excreted unchanged by the kidneys and its plasma levels are increased in patients with renal insufficiency [ 37 , 38 ] .", "label": "", "metadata": {}, "score": "81.271"}
{"text": "JAMA 285 : 2864 - 2870 . doi : 10.1001/jama.285.22.2864 .Oler A , Whooley MA , Oler J , Grady D ( 1996 )", "label": "", "metadata": {}, "score": "81.37127"}
{"text": "An effective way to \" discount \" for this limitation is to estimate the proportion of the warfarin treatment effect retained by each NOAC [ 25 ] , [ 30 ] , [ 31 ] .", "label": "", "metadata": {}, "score": "81.4518"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Olesen , G. Y. Lip , M. L. Hansen et al . , \" Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : nationwide cohort study , \" BMJ , vol .", "label": "", "metadata": {}, "score": "81.56146"}
{"text": "Thus , while patients on well - controlled warfarin are a lower priority regarding treatment with the new agents , they nevertheless would be expected to benefit .", "label": "", "metadata": {}, "score": "81.6535"}
{"text": "In order to evaluate the risk of MI or ACS with dabigatran , a meta - analysis of seven trials of dabigatran was conducted [ 51 ] .", "label": "", "metadata": {}, "score": "81.79962"}
{"text": "In this trial , 15 , 526 patients were randomized to receive either 2.5 mg or 5 mg placebo twice daily for a mean duration of 13 months .", "label": "", "metadata": {}, "score": "81.81571"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Nelson , J. P. Vavalle , C. H. May et al . , \" Warfarin use and long - term outcomes in patients with acute myocardial infarction and atrial fibrillation , \" Journal of Thrombosis and Thrombolysis , pp . 1 - 7 , 2013 .", "label": "", "metadata": {}, "score": "81.858536"}
{"text": "\"For NVAF patients for whom interruption of anticoagulation for a procedure is required , these findings suggest that using apixaban instead of warfarin , which is more challenging to stop and restart , may simplify the management of peri - operative anticoagulation in NVAF patients .", "label": "", "metadata": {}, "score": "81.87059"}
{"text": "With its compelling clinical profile , ELIQUIS represents the commitment of our partnership with Pfizer to scientific innovation and our shared vision of bringing innovative and meaningful medicines to patients . \"", "label": "", "metadata": {}, "score": "82.09985"}
{"text": "Much of this work has been led by investigators at Uppsala Clinical Research Institute and some of it in collaboration with investigators at Duke .While the mechanism of cardiac troponin elevation in patients with AF is not entirely understood , detecting an elevated level of cardiac troponin has been associated with an increased risk of stroke or systemic embolism and of cardiovascular death .", "label": "", "metadata": {}, "score": "82.14897"}
{"text": "Thromboembolic ( TE ) disease is a common cause of morbidity and mortality .Vitamin K antagonists ( VKAs ) such as warfarin are traditionally used for the prolonged management of thromboembolic disease .", "label": "", "metadata": {}, "score": "82.21245"}
{"text": "The CI was wider for those with diabetes because of the smaller number of participants with diabetes and their smaller total numbers of CVD events .", "label": "", "metadata": {}, "score": "82.23195"}
{"text": "The planned enrollment is 5,170 , and the investigators will examine several prespecified subgroups to detect differences in effect of aspirin , including men versus women and older versus younger age , as well as baseline lipid levels and use of statins .", "label": "", "metadata": {}, "score": "82.23277"}
{"text": "The RELY study included more than 18.000 patients with atrial fibrillation and a mean CHADS 2 -score of 2.1 randomized to dabigatran 110 mg bid , dabigatran 150 mg bid , or warfarin [ 22 ] .", "label": "", "metadata": {}, "score": "82.300705"}
{"text": "An important consideration is that patients may acquire additional risk factors over time , which would necessitate a reassessment of their overall risk profile .The absolute risk - based recommendations require the use of a risk prediction tool .", "label": "", "metadata": {}, "score": "82.416275"}
{"text": "Vitamin K antagonists ( VKA ) have long been the only oral anticoagulant agents available for effective thromboprophylaxis in patients with atrial fibrillation ( AF ) .", "label": "", "metadata": {}, "score": "82.43797"}
{"text": "With the aging of the population , the number of patients with AF is expected to increase 150 % by 2050 , with more than 50 % of AF patients being over the age of 80 [ 3 - 8 ] .", "label": "", "metadata": {}, "score": "82.47037"}
{"text": "In ARISTOTLE , a total of 15,916 ( 87.5 percent ) patients had a history of hypertension requiring treatment .Poorly controlled hypertension during the course of the trial was associated with a significant 53 percent increase in the risk of stroke or systemic embolism .", "label": "", "metadata": {}, "score": "82.65696"}
{"text": "In ARISTOTLE , a total of 15,916 ( 87.5 percent ) patients had a history of hypertension requiring treatment .Poorly controlled hypertension during the course of the trial was associated with a significant 53 percent increase in the risk of stroke or systemic embolism .", "label": "", "metadata": {}, "score": "82.65696"}
{"text": "Several indirect comparisons have been conducted between dabigatran , rivaroxaban and apixaban [ 10 ] - [ 15 ] .More recently , edoxaban emerged as the fourth NOAC in its class .", "label": "", "metadata": {}, "score": "82.70296"}
{"text": "Hess et al .analyzed the use of evidence based therapies for treating other cardiovascular existing risk factors .More than 93 % of patients in the registry were eligible for at least one guideline - based therapy for a coexisting cardiovascular disease , but only 46 % of patients received all recommended treatments , highlighting an opportunity to improve care [ 66 ] .", "label": "", "metadata": {}, "score": "82.859085"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , J. Oldgren , U. Andersson et al . , \" Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation : a randomized evaluation of long - term anticoagulation therapy ( RE - LY ) substudy , \" Circulation , vol .", "label": "", "metadata": {}, "score": "82.88459"}
{"text": "The lifetime risk of developing atrial fibrillation is estimated to be approximately 25 % for individuals 40 years of age or older .One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke , which is five times higher in people with atrial fibrillation than those without atrial fibrillation .", "label": "", "metadata": {}, "score": "82.93941"}
{"text": "The rate of warfarin use remained low over time , despite reductions in clopidogrel use from 6 to 12 months after discharge .These findings suggest that providers are using factors other than clinical risk stratification tools to guide anticoagulation decisions in high - risk patients .", "label": "", "metadata": {}, "score": "83.10159"}
{"text": "The best method is to compare drugs in large - scale head - to - head randomised trials , but this is unlikely to happen soon .", "label": "", "metadata": {}, "score": "83.14123"}
{"text": "This trial was conducted in parallel with the LANCELOT CAD trial , a phase II trial with patients with stable coronary artery disease [ 32 ] .", "label": "", "metadata": {}, "score": "83.157265"}
{"text": "Balloon angioplasty or the use of bare metal stents opposed to drug eluting stents can reduce the time of clopidogrel medication and should be preferred in patients requiring triple therapy [ 33 ] .", "label": "", "metadata": {}, "score": "83.210724"}
{"text": "The current guidelines of the European Society of Cardiology ( ESC ) for atrial fibrillation suggest risk stratification in patients with nonvalvular atrial fibrillation for the decision of implementing oral anticoagulation [ 1 ] .", "label": "", "metadata": {}, "score": "83.253784"}
{"text": "At the same time , the need for caution with their use in patients with severely impaired renal function should be emphasised .Introduction .Atrial fibrillation ( AF ) increases the risk of embolic stroke .", "label": "", "metadata": {}, "score": "83.331894"}
{"text": "The trials pooled in all of the meta - analyses varied widely in the CHD event rates in the control group .If the RR reduction ( the metric being pooled ) is consistent across patients of differing underlying absolute risk , as suggested by secondary prevention trials and the individual patient - level meta - analysis ( 5 ) , then such analyses seem to be reasonable .", "label": "", "metadata": {}, "score": "83.35225"}
{"text": "\" The marketing authorization for ELIQUIS is supported by the pivotal Phase 3 trials ARISTOTLE and AVERROES , which evaluated approximately 24,000 patients with NVAF in the largest completed clinical trial program conducted to date in this patient population .", "label": "", "metadata": {}, "score": "83.480934"}
{"text": "P - gp actively transports molecules with diverse conformations , including drugs , across tissue monolayers [ 35 ] .Compared to rivaroxaban and apixaban , oral dabigatran etexilate 's slow intestinal absorption renders it relatively more sensitive to p - gp efflux in the gut ( Figure 1 ) .", "label": "", "metadata": {}, "score": "83.56224"}
{"text": "9 , no .11 , pp .2153 - 2158 , 2011 .View at Google Scholar .G. Piaggio , D. R. Elbourne , D. G. Altman , S. J. Pocock , and S. J. W. Evans , \" Reporting of noninferiority and equivalence randomized trials : an extension of the CONSORT statement , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "83.65444"}
{"text": "doi : 10.1002/sim.1425 .Lee S , Shafe AC , Cowie MR ( 2011 ) UK stroke incidence , mortality and cardiovascular risk management 1999 - 2008 : time - trend analysis from the General Practice Research Database .", "label": "", "metadata": {}, "score": "83.80005"}
{"text": "The preservation of a pre - specified fraction of the benefit of the control drug by the test drug is a concept that is applied routinely in non - inferiority trials [ 30 ] .", "label": "", "metadata": {}, "score": "84.039185"}
{"text": "In aggregate , the four trials [ 3 ] - [ 6 ] accrued 71,683 patients .Table 1 shows the main features of the four studies [ 3 ] - [ 6 ] .", "label": "", "metadata": {}, "score": "84.18633"}
{"text": "10.2165/00002018 - 200831010 - 00006 View Article PubMed .Cohen AT , Spiro TE , B\u00fcller HR , Haskell L , Hu D , Hull R , Mebazaa A , Merli G , Schellong S , Spyropoulos AC , Tapson V , MAGELLAN Investigators : Rivaroxaban for thromboprophylaxis in acutely ill medical patients .", "label": "", "metadata": {}, "score": "84.28093"}
{"text": "An indirect comparison analysis .Thromb Haemost 111 .Epub ahead of print .In A Subanalysis , The Benefits Of Eliquis \u00ae ( apixaban )", "label": "", "metadata": {}, "score": "84.51495"}
{"text": "10.1185/03007990802361499 View Article PubMed .Kubitza D , Becka M , Voith B , Zuehlsdorf M , Wensing G : Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor .", "label": "", "metadata": {}, "score": "84.624916"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "Vs .Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "84.66092"}
{"text": "The incidence of ISTH major intraocular bleeding with ELIQUIS was 0.18%/year .About Atrial Fibrillation .Atrial fibrillation is the most common cardiac arrhythmia ( irregular heart beat ) .", "label": "", "metadata": {}, "score": "84.723404"}
{"text": "4 , pp .423 - 434 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Nieuwlaat , A. Capucci , A. J. Camm et al . , \" Atrial fibrillation management : a prospective survey in ESC Member Countries : the Euro Heart Survey on atrial fibrillation , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "84.7305"}
{"text": "Edoxaban is another factor Xa inhibitor that is likely to be FDA approved in the coming months .In this paper , we will not cover the edoxaban experience in the Effective Anticoagulation with Factor Xa", "label": "", "metadata": {}, "score": "84.877426"}
{"text": "doi : 10.7326/0003 - 4819 - 147 - 8 - 200710160 - 00018 .Husted S , De Caterina R , Andreotti F , Arnesen H , Bachmann F , et al .", "label": "", "metadata": {}, "score": "84.889175"}
{"text": "Erratum in : BMJ 2002;324:141 .JAMA 2001 ; 285 : 2486 - 2497 . :Blood Pressure Lowering Treatment Trialists ' Collaboration : Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus : results of prospectively designed overviews of randomized trials .", "label": "", "metadata": {}, "score": "85.15829"}
{"text": "For this purpose , the warfarin treatment effect was derived from a random - effects meta - analysis of 6 historical placebo - controlled trials [ 33 ] - [ 38 ] using the OR as the analysis metric .", "label": "", "metadata": {}, "score": "85.24428"}
{"text": "It should be used cautiously in patients with severely impaired renal function .It has no effect on the QTc interval [ 17 ] .Medically ill patients .", "label": "", "metadata": {}, "score": "85.33232"}
{"text": "Methods .Study selection .For RE - LY [ 3 ] , we integrated the original data with the update published in 2010 [ 21 ] .", "label": "", "metadata": {}, "score": "85.41164"}
{"text": "Markers of inflammation that have been studied in AF include interleukin-6 ( IL-6 ) and C - reactive protein ( CRP ) .Initially , a small study reported an association between IL-6 and a composite outcome of stroke and death [ 22 ] .", "label": "", "metadata": {}, "score": "85.76687"}
{"text": "10.1124/dmd.108.023143 View Article PubMed .Eriksson BI , Quinlan DJ , Weitz JI : Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development .", "label": "", "metadata": {}, "score": "85.894775"}
{"text": "For more than 150 years , Pfizer has worked to make a difference for all who rely on us . 1 Rao M , et al .", "label": "", "metadata": {}, "score": "85.917206"}
{"text": "For more than 150 years , Pfizer has worked to make a difference for all who rely on us . 1 Rao M , et al .", "label": "", "metadata": {}, "score": "85.917206"}
{"text": "It is important to understand if underuse of warfarin therapy in the elderly is due to appropriate reasons that may include the risk of bleeding and falls .", "label": "", "metadata": {}, "score": "85.92799"}
{"text": "By contrast , some differences exist between the four major trials versus warfarin [ 3 ] - [ 6 ] that could limit the validity of the similarity assumption by making unclear whether the different effects versus warfarin would be attributable to the NOAC alone .", "label": "", "metadata": {}, "score": "85.93967"}
{"text": "Atopaxar might have a diminished risk of bleeding compared with traditional antithrombotic drugs as it selectively reduces thrombin - mediated platelet activation but does not disrupt thrombin - dependent fibrin generation or ADP - dependent platelet activation [ 30 ] .", "label": "", "metadata": {}, "score": "85.96713"}
{"text": "Thus , \" nonvalvular \" AF is a misnomer .When used to identify the population for which the new drugs are not suitable this term should be limited to moderate or severe mitral stenosis or mechanical prosthetic valves .", "label": "", "metadata": {}, "score": "85.97824"}
{"text": ": American Heart Association , American Diabetes Association .Primary prevention of cardiovascular diseases in people with diabetes mellitus : a scientific statement from the American Heart Association and the American Diabetes Association .", "label": "", "metadata": {}, "score": "86.23875"}
{"text": "Additional Clinical Trials .A series of additional clinical trials have been planned or are underway to refine our understanding of use of the new oral anticoagulants for AF .", "label": "", "metadata": {}, "score": "86.32973"}
{"text": "In RE - LY , prospective open - label blinded endpoint evaluation ( PROBE ) trial design obviated the logistical difficulties of mounting a large - scale international double - blind VKA - controlled trial .", "label": "", "metadata": {}, "score": "86.33014"}
{"text": "The risk also appears to be increased by traumatic or repeated epidural or spinal puncture .Monitor patients for signs and symptoms of neurologic impairment .", "label": "", "metadata": {}, "score": "86.39412"}
{"text": "The risk also appears to be increased by traumatic or repeated epidural or spinal puncture .Monitor patients for signs and symptoms of neurologic impairment .", "label": "", "metadata": {}, "score": "86.39412"}
{"text": "The registry has now completed its three - year follow - up period .The ORBIT - AF registry includes approximately 200 sites and 10,000 patients , who are older than 18 years with AF and the ability to follow up every six months .", "label": "", "metadata": {}, "score": "86.396866"}
{"text": "As the burden of AF in the community greatly exceeds the capacity of specialist care , these NOACs open up opportunities for primary care physicians to initiate and maintain anticoagulation treatment in the wider , hitherto undertreated , group of eligible patients with AF .", "label": "", "metadata": {}, "score": "86.4299"}
{"text": "A prospective randomized trial would be sensible but is unlikely to be conducted .PAR-1 Receptor Antagonists .The protease - activated receptor-1 ( PAR-1 ) thrombin receptor antagonists atopaxar and vorapaxar represent a novel approach to the inhibition of platelet activation .", "label": "", "metadata": {}, "score": "86.47033"}
{"text": "The most robust result in a noninferiority trial would be to demonstrate consistency of the on - treatment and intention - to - treat analyses , but this is not always achievable in practice [ 7 - 9 , 13 ] .", "label": "", "metadata": {}, "score": "86.61937"}
{"text": "Reduced renal function can be measured by calculations of glomerular filtration rates ( GFR ) , based on creatinine , or by cystatin C , which is a small protein that is freely filtered by the glomerulus .", "label": "", "metadata": {}, "score": "86.63466"}
{"text": "Careful analyses have defined the treatment effect of the new drugs versus warfarin according to time in therapeutic range for warfarin - treated patients at the site level .", "label": "", "metadata": {}, "score": "86.639984"}
{"text": "2370 - 2375 , 2001 .View at Google Scholar \u00b7 View at Scopus . A. J. Camm , P. Kirchhof , G. Y. Lip , et al . , \" Guidelines for the management of atrial fibrillation : the task force for the management of atrial fibrillation of the European Society of Cardiology ( ESC ) , \" Europace , vol .", "label": "", "metadata": {}, "score": "86.64212"}
{"text": "236 - 241 , 1994 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Miyasaka , M. E. Barnes , B. J. Gersh et al . , \" Secular trends in incidence of atrial fibrillation in Olmsted County , Minnesota , 1980 to 2000 , and implications on the projections for future prevalence , \" Circulation , vol .", "label": "", "metadata": {}, "score": "86.793045"}
{"text": "Search strategy and selection of clinical trial according to the PRISMA ( Preferred Reporting Items for Systematic reviews and Meta - Analyses ) statement for reporting systematic reviews and meta - analyses .", "label": "", "metadata": {}, "score": "86.91877"}
{"text": "Warfarin use at discharge following acute myocardial infarction according to CHADS2 and CHA2DS2-VASc scores [ 24 ] .Percentages of medication use were visually estimated from primary publication .", "label": "", "metadata": {}, "score": "87.07187"}
{"text": "A meta - analysis .JAMA 276 : 811 - 815 .doi : 10.1001/jama.1996.03540100055028 .Antman EM , McCabe CH , Gurfinkel EP , Turpie AG , Bernink PJ , et al .", "label": "", "metadata": {}, "score": "87.23364"}
{"text": "Vitamin K antagonists interfere with the biosyntheses of coagulation factors and thus achieve effective levels of anticoagulation only after several days , and their effect diminishes slowly after withdrawal .", "label": "", "metadata": {}, "score": "87.29708"}
{"text": "ARISTOTLE was an active - controlled , randomized , double - blind , multi - national trial in patients with nonvalvular atrial fibrillation or atrial flutter , and at least one additional risk factor for stroke .", "label": "", "metadata": {}, "score": "87.34117"}
{"text": "ARISTOTLE was an active - controlled , randomized , double - blind , multi - national trial in patients with nonvalvular atrial fibrillation or atrial flutter , and at least one additional risk factor for stroke .", "label": "", "metadata": {}, "score": "87.34117"}
{"text": "Thromb Haemost 108 : 405 - 406 .doi : 10.1160/th12 - 06 - 0438 .Liberati A , Altman DG , Tetzlaff J , Mulrow C , Gotzsche PC , et al .", "label": "", "metadata": {}, "score": "87.42525"}
{"text": "About the Bristol - Myers Squibb / Pfizer Collaboration .In 2007 , Pfizer and Bristol - Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis , an oral anticoagulant discovered by Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "87.46779"}
{"text": "About the Bristol - Myers Squibb / Pfizer Collaboration .In 2007 , Pfizer and Bristol - Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis , an oral anticoagulant discovered by Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "87.46779"}
{"text": "About the Bristol - Myers Squibb / Pfizer Collaboration .In 2007 , Pfizer and Bristol - Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis , an oral anticoagulant discovered by Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "87.46779"}
{"text": "The ESC guidelines on atrial fibrillation also provide a risk score to assess the haemorrhagic risk : the HAS - BLED - Score ( Table 2 ) [ 1 ] .", "label": "", "metadata": {}, "score": "87.597275"}
{"text": "TF - VIIa complexes are suppressed by VKAs , which block vitamin K - dependent carboxylation of factor VII , but not by NOACs with their more highly selective targets .", "label": "", "metadata": {}, "score": "87.60402"}
{"text": "Thromb Haemost 111 : 781 - 782 .doi : 10.1160/th14 - 03 - 0228 .Camm AJ , Lip GY , De Caterina R , Savelieva I , Atar D , et al .", "label": "", "metadata": {}, "score": "87.615425"}
{"text": "638.e4 - 645 . e4 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Wilke , A. Groth , S. Mueller , et al . , \" Oral anticoagulation use by patients with atrial fibrillation in Germany .", "label": "", "metadata": {}, "score": "87.63404"}
{"text": "There were significant reductions in ICH that mirror the significant RRRs observed in haemorrhagic stroke events .Taken together , they suggest a brain - protective effect for these NOACs , the exact mechanism of which remains to be elucidated .", "label": "", "metadata": {}, "score": "87.846146"}
{"text": "For example , the CHA2DS2-VASc score has a C - statistic of 0.55 - 0.64 , where 1.0 would represent the perfect ability to correctly rank risk and 0.5 would indicate correct classification only half the time or random chance [ 15 ] .", "label": "", "metadata": {}, "score": "88.08205"}
{"text": "The ORBIT - AF II registry has started to enroll .Similar to ORBIT - AF , ORBIT - AF II is a multicentered prospective outpatient registry ; however , this registry will focus on postapproval observational data to evaluate outcomes of novel oral anticoagulant therapies in a broader outpatient setting .", "label": "", "metadata": {}, "score": "88.11128"}
{"text": "Poster presented at : American College of Cardiology 2014 Scientific Session ; March 29 , 2014 ; Washington , DC .You are here .Home \" News & Media \" Press Releases \" In A Subanalysis , The Benefits Of Eliquis \u00ae ( apixaban )", "label": "", "metadata": {}, "score": "88.13196"}
{"text": "Observational studies , phase 1 and phase 2 trials were excluded .We also excluded personal opinions , editorials , correspondences and perspective articles .Full text versions of the included articles were downloaded and evaluated by the authors to compile a narrative review on the field ( Figure 2 ) .", "label": "", "metadata": {}, "score": "88.27563"}
{"text": "A randomised , double - blind , non - inferiority trial .Thromb Haemost 2011 , 105(4):721 - 729 .10.1160/TH10 - 10 - 0679", "label": "", "metadata": {}, "score": "88.573364"}
{"text": "A global registry called the RE - LY registry , including 47 countries with 15,174 patients with AF , was created to determine if there were differences in the treatment of AF globally [ 64 ] .", "label": "", "metadata": {}, "score": "88.60395"}
{"text": "No other potential conflicts of interest relevant to this article were reported .Footnotes .Peer - reviewed by the American Diabetes Association , the American Heart Association , and the American College of Cardiology Foundation November 2009 and revised January 2010 ; approved by all three organizations March 2010 .", "label": "", "metadata": {}, "score": "88.975174"}
{"text": "492 - 501 , 1999 .View at Google Scholar \u00b7 View at Scopus .M. Nabauer , A. Gerth , T. Limbourg et al . , \" The registry of the German competence NETwork on atrial fibrillation : patient characteristics and initial management , \" Europace , vol .", "label": "", "metadata": {}, "score": "88.98266"}
{"text": "Table 4 summarises the efficacy outcomes in the active treatment groups , expressed as relative risk reductions ( RRRs ) or increments of event rates , compared to VKA - controlled populations in the trials [ 13 - 15 , 21 ] .", "label": "", "metadata": {}, "score": "89.06624"}
{"text": "Eliquis is approved for prevention of venous thromboembolic events ( VTE ) in adult patients who have undergone elective hip or knee replacement surgery in the European Union ( which includes 28 member states plus Iceland and Norway ) and a number of other countries around the world .", "label": "", "metadata": {}, "score": "89.072784"}
{"text": "Edoxaban .Edoxaban is a rapidly absorbed active drug with a half life of 9 - 11 hours [ 4 , 31 ] .An RCT has demonstrated that the effect of food on the pharmacokinetic properties of the drug is clinically insignificant [ 32 ] .", "label": "", "metadata": {}, "score": "89.34431"}
{"text": "10.1016/j.clpt.2005.06.011 View Article PubMed .Kubitza D , Mueck W , Becka M : Randomized , double - blind , crossover study to investigate the effect of rivaroxaban on QT - interval prolongation .", "label": "", "metadata": {}, "score": "89.42287"}
{"text": "The increased risk for cardiovascular events and mortality in patients with diabetes has led to considerable interest in identifying effective means for cardiovascular risk reduction .", "label": "", "metadata": {}, "score": "89.48448"}
{"text": "doi : 10.1016/j.jval.2011.01.011 .Jansen JP , Fleurence R , Devine B , Itzler R , Barrett A , et al .( 2011 )", "label": "", "metadata": {}, "score": "89.55858"}
{"text": "No single trial provides definitive results .As such , we sought , in question 2 , to use meta - analysis to try to reconcile the available data .", "label": "", "metadata": {}, "score": "90.02157"}
{"text": "However , the indirect comparison analysis has well recognized inherent limitations [ 16 ] , [ 17 ] .It assumes that the differences tested in the analysis between any NOAC and the common comparator ( warfarin in our case ) would have been similar ( ' similarity assumption ' ) also in the context of a different trial population exposed to a different NOAC .", "label": "", "metadata": {}, "score": "90.39896"}
{"text": "Consequently , all NOACs retained more that 100 % of the benefit of warfarin with the exception of edoxaban 30 % that , however , retained 87 % of its benefit .", "label": "", "metadata": {}, "score": "90.78667"}
{"text": "10.1056/NEJMoa076016 View Article PubMed .Lancet 2009 , 373(9676):1673 - 1680 .10.1016/S0140 - 6736(09)60734 - 0 View Article PubMed .Eur Heart J 2011 , 32(19):2387 - 2394 .", "label": "", "metadata": {}, "score": "90.835976"}
{"text": "Impaired Renal Function .Patients with AF and renal impairment are at high risk for thromboembolism and also for bleeding .Given the higher drug concentrations of the novel anticoagulants with decreased renal excretion , it is important to consider the risk of bleeding in this high - risk population .", "label": "", "metadata": {}, "score": "90.92151"}
{"text": "New Drugs for Oral Anticoagulation in Combination with Antiplatelet Therapy .The results of the three large studies RELY , ARISTOTLE , and ROCKET - AF are very promising .", "label": "", "metadata": {}, "score": "90.943794"}
{"text": "Table 5 summarises the safety outcomes in the active treatment groups , expressed as RRR or increments of event rates , compared to VKA - controlled populations .", "label": "", "metadata": {}, "score": "91.17875"}
{"text": "Based on the information gathered through the interviewing process , a practice toolkit that contains a series of tools that address the gaps and barriers to quality care will be developed and shared with all participants .", "label": "", "metadata": {}, "score": "91.22981"}
{"text": "In the present study , we tried to put the results of ENGAGE AF - TIMI 48 trial [ 6 ] in the scenario of available outcome data on NOACs .", "label": "", "metadata": {}, "score": "91.37102"}
{"text": "Imputed placebo analysis .This kind of analysis is increasingly performed to estimate how might be the effect of a new treatment if compared versus placebo in the case that a placebo - controlled trial with the new agent would be unethical or unfeasible .", "label": "", "metadata": {}, "score": "91.41193"}
{"text": "The main novel finding of the present study is the estimate , obtained through an imputed placebo analysis , of the proportion of warfarin effect preserved by all NOACs on stroke and all - cause mortality in patients with non valvular AF .", "label": "", "metadata": {}, "score": "91.73657"}
{"text": "There has been an explosion of data emanating from these trial databases and from registries over the past 5 years which is redefining much of the knowledge around antithrombotic therapy for AF .", "label": "", "metadata": {}, "score": "91.7662"}
{"text": "The estimated proportion of warfarin benefit retained on stroke is shown in figure 4 .The estimated proportion of warfarin benefit retained on all - cause mortality is shown in figure 5 .", "label": "", "metadata": {}, "score": "91.97357"}
{"text": "This trial will start enrolling patients in 2014 and will follow them for one year .Implementation of Demonstration Project for Health Systems , Atrial Fibrillation ( INFORM - AF ) , is a separate initiative underway that we designed to improve treatment for stroke prevention in AF in the United States health systems .", "label": "", "metadata": {}, "score": "92.12991"}
{"text": "However , the weight of evidence shall have to lie chiefly with RE - LY , the largest trial for dabigatran , which ultimately did not demonstrate a statistically significant increase in MI risk .", "label": "", "metadata": {}, "score": "92.182846"}
{"text": "Acknowledgments .The authors thank the ATT Collaboration Secretariat for generously sharing diabetic sub - group data ; and Dan Jonas , MD , MPH , RTI - UNC Evidence - Based Practice Center , for his assistance with the meta - analyses .", "label": "", "metadata": {}, "score": "92.19766"}
{"text": "Relevant details of the pharmacokinetic properties of the drugs were added to complete the drug profile independent of the above mentioned literature search .Apixaban .", "label": "", "metadata": {}, "score": "92.25594"}
{"text": "HR devised the manuscript , FT and HR did the literature search .FT , HR and TR wrote the manuscript .IBR edited the manuscript , HM and AH did the final revision .", "label": "", "metadata": {}, "score": "92.93962"}
{"text": "In states of cardiovascular hemodynamic stress , the neurohormone B - type natriuretic peptide ( BNP ) is secreted from myocytes and BNP or its inactive N - terminal fragment ( NT - proBNP ) can be detected in the serum .", "label": "", "metadata": {}, "score": "93.01225"}
{"text": "However , none of the subgroups analyses of any NOAC versus warfarin on the primary outcome was statistically significant for interaction by CHADS 2 score [ 3 ] - [ 6 ] .", "label": "", "metadata": {}, "score": "93.03271"}
{"text": "Methods and Findings .We performed a literature search ( up to January 2014 ) , clinical trials registers , conference proceedings , and websites of regulatory agencies .", "label": "", "metadata": {}, "score": "93.04204"}
{"text": "The procedures were classified as major if they required general anesthesia , and procedures were also classified as emergent or non - emergent by investigators .", "label": "", "metadata": {}, "score": "93.113625"}
{"text": "PRINCETON , N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol - Myers Squibb Company ( BMY ) and Pfizer Inc. ( PFE ) today announced results of a post - hoc subanalysis from the Phase III ARISTOTLE trial .", "label": "", "metadata": {}, "score": "93.14592"}
{"text": "We will use qualitative interviewing to develop a system to categorize patients according to reasons for withholding anticoagulation therapy with the goal of defining performance indicators that can be used for quality assessment of AF therapy within health care systems and clinical practices .", "label": "", "metadata": {}, "score": "93.346054"}
{"text": "The authors have no support or funding to report .Competing interests : This work has not been supported from any Pharmaceutical Company .This does not alter the authors ' adherence to PLOS ONE policies on sharing data and materials .", "label": "", "metadata": {}, "score": "93.85367"}
{"text": "Value Health 14 : 417 - 428 .doi : 10.1016/j.jval.2011.04.002 .Gage BF , Waterman AD , Shannon W , Boechler M , Rich MW , et al .", "label": "", "metadata": {}, "score": "94.19537"}
{"text": "Introduction .Atrial fibrillation ( AF ) is the most common arrhythmia and accounts for one - third of hospitalizations for rhythm disorders in the United States [ 1 ] .", "label": "", "metadata": {}, "score": "94.45157"}
{"text": "Food does not affect its absorption from the gastrointestinal tract .It has a dual mode of elimination , since one - third of the active drug is excreted unchanged renally while two - thirds of the drug undergoes hepatic metabolism .", "label": "", "metadata": {}, "score": "94.50863"}
{"text": "The safety and efficacy outcomes of the RELY , ROCKET - AF , and ARISTOTLE study are depicted in Figure 1 .Figure 1 : GI : gastrointestinal , ICH : intracerebral hemorrhage .", "label": "", "metadata": {}, "score": "94.79697"}
{"text": "12 , pp .857 - 867 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . \"The Atrial Fibrillation Investigators .", "label": "", "metadata": {}, "score": "94.878815"}
{"text": "The planned enrollment is 10,000 , which was designed to provide adequate power to detect a 20 % reduction in major vascular events including both MI and stroke .", "label": "", "metadata": {}, "score": "94.97257"}
{"text": "19 , pp .2387 - 2394 , 2011 .View at Google Scholar .123 , no .21 , pp .2363 - 2372 , 2011 .", "label": "", "metadata": {}, "score": "95.221146"}
{"text": "Developed with the special contribution of the European Heart Rhythm Association .Eur Heart J 33 : 2719 - 2747 . doi : 10.1093/eurheartj / eht027 .", "label": "", "metadata": {}, "score": "95.362366"}
{"text": "The PRISMA statement for reporting systematic reviews and meta - analyses of studies that evaluate health care interventions : explanation and elaboration .PLoS Med 6 : e1000100 . doi : 10.1371/journal.pmed.1000100 .", "label": "", "metadata": {}, "score": "95.67561"}
{"text": "Circulation 100 : 1593 - 1601 .doi : 10.1161/01 .cir.100.15.1593 .Ruff CT , Giugliano RP , Braunwald E , Hoffman EB , Deenadayalu N , et al .", "label": "", "metadata": {}, "score": "95.9742"}
{"text": "N Engl J Med 2010 , 363(26):2499 - 2510 .View Article PubMed .N Engl J Med 2012 , 366(14):1287 - 1297 .View Article PubMed .", "label": "", "metadata": {}, "score": "96.31874"}
{"text": "Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation .Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators .N Engl J Med 327 : 1406 - 1412 .", "label": "", "metadata": {}, "score": "96.85747"}
{"text": "10.1056/NEJMoa1112277 View Article PubMed .Blood 2008 , 112(6):2242 - 2247 .10.1182/blood-2008 - 05 - 160143 View Article PubMed .Circulation 2007 , 116(2):180 - 187 .", "label": "", "metadata": {}, "score": "97.06363"}
{"text": "doi : 10.1111/j.1742 - 1241.2009.02072.x .Hoaglin DC , Hawkins N , Jansen JP , Scott DA , Itzler R , et al .", "label": "", "metadata": {}, "score": "97.12247"}
{"text": "J Clin Pharmacol 2005 , 45(5):555 - 563 .10.1177/0091270005274550 View Article PubMed .Lancet 2007 , 370(9591):949 - 956 .10.1016/S0140 - 6736(07)61445 - 7 View Article PubMed .", "label": "", "metadata": {}, "score": "97.29446"}
{"text": "Lancet 342 : 1255 - 1262 .doi : 10.1016/0140 - 6736(93)92358-z .Petersen P , Boysen G , Godtfredsen J , Andersen ED , Andersen B ( 1989 )", "label": "", "metadata": {}, "score": "97.30894"}
{"text": "Several prospective studies are currently conducted to assess the use of dual and triple therapy in patients with atrial fibrillation after stent implantation .The study is estimated to be completed in December 2012 with about 300 enrolled patients [ 10 ] .", "label": "", "metadata": {}, "score": "97.46811"}
{"text": "Figure 1 : Dabigatran etexilate : a p - gp substrate .Using energy from adenosine triphosphate , p - gp receptors in the intestinal wall actively transport molecules across the epithelial monolayer .", "label": "", "metadata": {}, "score": "97.96761"}
{"text": "Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent , Regardless Of Blood Pressure Control 1 .You are here .", "label": "", "metadata": {}, "score": "98.15016"}
{"text": "Literature search criteria .The articles were then manually examined to exclude the duplicate entries .Search was limited from January 2007 to February 2013 .", "label": "", "metadata": {}, "score": "98.26569"}
{"text": "10 , pp .1360 - 1420 , 2010 .View at Google Scholar .123 , no .10 , pp .e269-e367 , 2011 .", "label": "", "metadata": {}, "score": "98.9044"}
{"text": "The excess risk may be as high as 1 - 5 per 1,000 per year in real - world settings .We have developed recommendations based on these data .", "label": "", "metadata": {}, "score": "99.087105"}
{"text": "( ACCF / AHA Class III , Level of Evidence C ) ( ADA Level of Evidence C ) .( ACCF / AHA Class IIb , Level of Evidence C ) ( ADA Level of Evidence E ) .", "label": "", "metadata": {}, "score": "99.13458"}
{"text": "The authors declare that there is no conflict of interests regarding the publication of this paper .Acknowledgments .Meena P. Rao M.D. MPH received research / research grants from Medtronic Foundation ; consultant fees / honoraria were provided by Daiichi Sanyko .", "label": "", "metadata": {}, "score": "99.72765"}
{"text": "doi : 10.1016/j.thromres.2012.08.005 .PLoS One 8 : e77694 . doi : 10.1371/journal.pone.0077694 .Song F , Loke YK , Walsh T , Glenny AM , Eastwood AJ , et al .", "label": "", "metadata": {}, "score": "99.78476"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .The authors declared that they have no competing interest .", "label": "", "metadata": {}, "score": "99.802315"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b1477 - 9560 - 11 - 18 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "101.30481"}
{"text": "The Copenhagen AFASAK study .Lancet 1 : 175 - 179 .doi : 10.1016/s0140 - 6736(89)91200 - 2 .Ezekowitz MD , Bridgers SL , James KE , Carliner NH , Colling CL , et al .", "label": "", "metadata": {}, "score": "101.41058"}
{"text": "N Engl J Med 2011 , 365(10):883 - 891 .10.1056/NEJMoa1009638 View Article PubMed .Lancet 2009 , 374(9683):29 - 38 .10.1016/S0140 - 6736(09)60738 - 8 View Article PubMed .", "label": "", "metadata": {}, "score": "101.95116"}
{"text": "At Pfizer , we apply science and our global resources to bring therapies to people that extend and significantly improve their lives .We strive to set the standard for quality , safety and value in the discovery , development and manufacture of health care products .", "label": "", "metadata": {}, "score": "102.32581"}
{"text": "At Pfizer , we apply science and our global resources to bring therapies to people that extend and significantly improve their lives .We strive to set the standard for quality , safety and value in the discovery , development and manufacture of health care products .", "label": "", "metadata": {}, "score": "102.32581"}
{"text": "At Pfizer , we apply science and our global resources to bring therapies to people that extend and significantly improve their lives .We strive to set the standard for quality , safety and value in the discovery , development and manufacture of health care products .", "label": "", "metadata": {}, "score": "102.32581"}
{"text": "Atrial fibrillation is the most common arrhythmia and accounts for one - third of hospitalizations for rhythm disorders in the United States .The prevalence of atrial fibrillation averages 1 % and increases with age .", "label": "", "metadata": {}, "score": "102.40794"}
{"text": "10 , pp . 883 - 891 , 2011 .View at Publisher \u00b7 View at Google Scholar .123 , no .21 , pp .", "label": "", "metadata": {}, "score": "102.58665"}
{"text": "447 - 451 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .370 , no .9586 , pp .", "label": "", "metadata": {}, "score": "103.07464"}
{"text": "9775 , pp .1409 - 1420 , 2011 .View at Publisher \u00b7 View at Google Scholar .122 , no .24 , pp .", "label": "", "metadata": {}, "score": "103.32872"}
{"text": "10.1111/j.1538 -7836.2010.04021.x View Article PubMed .Thromb Haemost 2010 , 104(3):633 - 641 .10.1160/TH10 - 01 - 0066 View Article PubMed .", "label": "", "metadata": {}, "score": "103.511154"}
{"text": "19 , pp .1788 - 1790 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 285 , no .", "label": "", "metadata": {}, "score": "103.90343"}
{"text": "Such forward - looking statements are based on current expectations and involve inherent risks and uncertainties , including factors that could delay , divert or change any of them , and could cause actual outcomes and results to differ materially from current expectations .", "label": "", "metadata": {}, "score": "104.38214"}
{"text": "4 , pp .506 - 509 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 285 , no .", "label": "", "metadata": {}, "score": "104.65706"}
{"text": "10 , pp .946 - 952 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .137 , no . 2 , pp .", "label": "", "metadata": {}, "score": "105.291145"}
{"text": "Lancet 383 : 955 - 962 .doi : 10.1016/s0140 - 6736(13)62343 - 0 .Skjoth F , Larsen TB , Rasmussen LH , Lip GY ( 2014 )", "label": "", "metadata": {}, "score": "105.3149"}
{"text": "28 , no .10 , pp .973 - 977 , 1978 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "105.92594"}
{"text": "Every day , Pfizer colleagues work across developed and emerging markets to advance wellness , prevention , treatments and cures that challenge the most feared diseases of our time .", "label": "", "metadata": {}, "score": "106.32796"}
{"text": "Every day , Pfizer colleagues work across developed and emerging markets to advance wellness , prevention , treatments and cures that challenge the most feared diseases of our time .", "label": "", "metadata": {}, "score": "106.32796"}
{"text": "Every day , Pfizer colleagues work across developed and emerging markets to advance wellness , prevention , treatments and cures that challenge the most feared diseases of our time .", "label": "", "metadata": {}, "score": "106.32796"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus The burden of cardiovascular disease ( CVD ) among patients with diabetes is substantial .", "label": "", "metadata": {}, "score": "106.73489"}
{"text": "Centers for Disease Control and Prevention .National Diabetes Fact Sheet : General Information and National Estimates on Diabetes in the United States , 2007 .", "label": "", "metadata": {}, "score": "106.74957"}
{"text": "About Atrial Fibrillation .Atrial fibrillation is the most common cardiac arrhythmia ( irregular heartbeat ) .It is estimated that approximately 5.8 million Americans and six million individuals in Europe have atrial fibrillation .", "label": "", "metadata": {}, "score": "106.87761"}
{"text": "About Atrial Fibrillation .Atrial fibrillation is the most common cardiac arrhythmia ( irregular heartbeat ) .It is estimated that approximately 5.8 million Americans and six million individuals in Europe have atrial fibrillation .", "label": "", "metadata": {}, "score": "106.87761"}
{"text": "P - gp efflux transporters in the blood - brain barrier provide protection against entry of potential noxious endogenous and exogenous compounds , and have been implicated in development of resistance to oncological and microbiological therapeutic agents [ 64 ] .", "label": "", "metadata": {}, "score": "107.41032"}
{"text": "For more than 150 years , Pfizer has worked to make a difference for all who rely on us .Bristol - Myers Squibb Forward - Looking Statement .", "label": "", "metadata": {}, "score": "107.43733"}
{"text": "1 These data will be presented Saturday , March 29 , at the American College of Cardiology 's ( ACC ) 63rd Annual Scientific Session in Washington , D.C. . \"", "label": "", "metadata": {}, "score": "107.4683"}
{"text": "1 These data will be presented Saturday , March 29 , at the American College of Cardiology 's ( ACC ) 63rd Annual Scientific Session in Washington , D.C. . \"", "label": "", "metadata": {}, "score": "107.4683"}
{"text": "462 - 466 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .38 , no .4 , pp .", "label": "", "metadata": {}, "score": "107.9469"}
{"text": "119 - 125 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .271 , no .11 , pp .", "label": "", "metadata": {}, "score": "108.47827"}
{"text": "18 , pp .2067 - 2070 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .374 , no .", "label": "", "metadata": {}, "score": "108.59035"}
{"text": "11 , pp .893 - 900 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .166 , pp .", "label": "", "metadata": {}, "score": "109.04733"}
{"text": "The information contained in this release is as of August 31 , 2013 .Pfizer assumes no obligation to update forward - looking statements contained in this release as the result of new information or future events or developments .", "label": "", "metadata": {}, "score": "109.27328"}
{"text": "157 , no .11 , pp .1237 - 1240 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "109.56116"}
{"text": "Atrial fibrillation is the most common cardiac arrhythmia ( irregular heart beat ) .It is estimated that approximately 5.8 million Americans and six million individuals in Europe have atrial fibrillation .", "label": "", "metadata": {}, "score": "109.78966"}
{"text": "810 - 815 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .137 , no . 2 , pp .", "label": "", "metadata": {}, "score": "109.82909"}
{"text": "123 , no .17 , pp .1843 - 1853 , 2011 .View at Publisher \u00b7 View at Google Scholar .158 , no . 3 , pp .", "label": "", "metadata": {}, "score": "110.43245"}
{"text": "159 - 168 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .125 , no . 3 , pp .", "label": "", "metadata": {}, "score": "111.34383"}
{"text": "31 , no .11 , pp .1311 - 1318 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "111.86949"}
{"text": "369 , no .9562 , pp .667 - 678 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.055435"}
{"text": "Atrial Fibrillation : A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute .Cardiology Division , Duke University Hospital , 2301 Erwin Road , DUMC 3845 , Durham , NC 27710 , USA .", "label": "", "metadata": {}, "score": "112.20775"}
{"text": "Authors ' Affiliations .Dow Medical College , Dow University of Health Sciences .Department of Medicine , Indiana University .Department of Medicine , University of Arizona .", "label": "", "metadata": {}, "score": "112.69365"}
{"text": "147 , no . 9 , pp .1561 - 1564 , 1987 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "113.00693"}
{"text": "Cell - surface tissue factor ( TF ) , which is found in high concentrations in the brain , may offer an explanation [ 59 ] .", "label": "", "metadata": {}, "score": "113.1313"}
{"text": "10.1056/NEJMoa0906598 View Article PubMed .Copyright .\u00a9 Tahir et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Search Life Sciences Jobs .", "label": "", "metadata": {}, "score": "113.66321"}
{"text": "doi:10.1371/journal.pone.0100478 .Editor : Adrian V. Hernandez , Universidad Peruana de Ciencias Aplicadas ( UPC ) , Peru .Received : February 27 , 2014 ; Accepted : May 26 , 2014 ; Published : June 23 , 2014 .", "label": "", "metadata": {}, "score": "113.80551"}
{"text": "Poster presented at : American College of Cardiology 2014 Scientific Session ; March 29 , 2014 ; Washington , DC .Copyright \u00a9 2002 - 2016 Pfizer Inc.", "label": "", "metadata": {}, "score": "114.03644"}
{"text": "J Arthroplasty 2009 , 24(1):1 - 9 .View Article PubMed .N Engl J Med 2009 , 361(12):1139 - 1151 .10.1056/NEJMoa0905561 View Article PubMed .", "label": "", "metadata": {}, "score": "114.36383"}
{"text": "Bristol - Myers Squibb undertakes no obligation to publicly update any forward - looking statement , whether as a result of new information , future events or otherwise .", "label": "", "metadata": {}, "score": "114.623085"}
{"text": "1105 - 1114 , 2013 .View at Google Scholar .285 , no .22 , pp .2864 - 2870 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "114.64575"}
{"text": "625.e1 - 632 .e1 , 2013 .View at Publisher \u00b7 View at Google Scholar .6 , no .4 , pp .461 - 469 , 2013 .", "label": "", "metadata": {}, "score": "116.718994"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .367 , no .9526 , pp .1903 - 1912 , 2006 .", "label": "", "metadata": {}, "score": "121.0361"}
{"text": "74 - 90 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus", "label": "", "metadata": {}, "score": "121.71414"}
{"text": "This information - including product information - is intended only for residents of the United States .The products discussed herein may have different labeling in different countries .", "label": "", "metadata": {}, "score": "123.36096"}
{"text": "About Bristol - Myers Squibb .Bristol - Myers Squibb is a global biopharmaceutical company whose mission is to discover , develop and deliver innovative medicines that help patients prevail over serious diseases .", "label": "", "metadata": {}, "score": "126.84677"}
{"text": "About Bristol - Myers Squibb .Bristol - Myers Squibb is a global biopharmaceutical company whose mission is to discover , develop and deliver innovative medicines that help patients prevail over serious diseases .", "label": "", "metadata": {}, "score": "126.84677"}
{"text": "About Bristol - Myers Squibb .Bristol - Myers Squibb is a global biopharmaceutical company whose mission is to discover , develop and deliver innovative medicines that help patients prevail over serious diseases .", "label": "", "metadata": {}, "score": "126.84677"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .138 , no .5 , pp .1093 - 1100 , 2010 .", "label": "", "metadata": {}, "score": "128.92348"}
{"text": "View at Google Scholar .160 , no .5 , pp .804 - 811 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "131.25525"}
{"text": "This is an open - access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited .", "label": "", "metadata": {}, "score": "137.0635"}
{"text": "Received 9 November 2011 ; Accepted 2 February 2012 .Academic Editor : Louis M. Aledort .Copyright \u00a9 2012 Karl Mischke et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "138.10924"}
{"text": "Academic Editor : Walter Ageno .Copyright \u00a9 2012 Tan Ru San et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "142.77231"}
{"text": "Academic Editor : Lei Xi .Copyright \u00a9 2014 Meena P. Rao et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "144.06194"}
